Document:

Stock Purchase Agreement

 Exhibit 4.1 
  
 STOCK PURCHASE AGREEMENT 
  
 THIS STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of April 7, 2005, by and among Curon Medical, Inc., a Delaware corporation (the
“Company”), and the investors listed on Schedule I hereto (“Investors”). 
  
 1. Purchase and Sale of Stock. Subject to the terms and conditions of this Agreement, Investors agree to purchase at the First Closing (as
hereinafter defined), and the Company agrees to sell and issue to each of the Investors at the First Closing, that number of whole shares of the Company’s common stock (the “Common Stock”) set forth opposite each Investor’s name
on Schedule I hereto (collectively, the “First Closing Shares”). In addition, Investors agree to purchase at the Second Closing (as hereinafter defined), contingent solely upon the Stockholder Approval Event (as hereinafter
defined), and the Company agrees to sell and issue to such Investors at the Second Closing, that number of whole shares of the Company’s Common Stock set forth opposite each Investor’s name on Schedule I hereto (collectively, the
“Second Closing Shares,” and, together with the First Closing Shares, the “Shares”). The purchase price per share for the Shares shall be $0.65 (the “Purchase Price”). In consideration thereof, the Company shall also
issue warrants to the Investors in substantially the form of Exhibit A hereto (warrants issued in connection with the First Closing, the “First Closing Warrants,” and warrants issued in connection with the Second Closing, the
“Second Closing Warrants,” and, together, the “Warrants;” and the Warrants together with the Shares, the “Securities”) for the purchase of 0.5 shares of Common Stock (the “Warrant Shares”) for each share of
Common Stock issued to such Investors hereunder. 
  
 1.1 First
Closing. The first closing of the purchase and sale of Shares (the “First Closing”) shall be held at the offices of Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California (“WSGR”), on April 8,
2005 at 9:00 a.m., or at such other time and place upon which the Company and Investors shall agree. The amount of Securities to be issued in the First Closing shall, in any event, be less than that amount of Securities which issuance would require
stockholder approval as specified by the Marketplace Rules of the Nasdaq Stock Market. 
  
 1.2 Second Closing. The second closing of the purchase and sale of Shares (the “Second Closing,” the First Closing and the Second Closing shall each be a “Closing”) shall be held at the
offices of WSGR, as soon as practicable after the satisfaction or inapplicability of the Stockholder Approval Event (as hereinafter defined). Payment of the purchase price for the Second Closing Shares and the Second Closing Warrants shall be
deposited with Mellon Investor Services LLC (the “Escrow Agent”) by wire transfer of same day funds concurrent with the payment for the Securities to be sold and issued in the First Closing (the “Escrowed Funds”). 
  
 1.3 Delivery. Within three business days of the applicable Closing, as
the case may be, the Company shall deliver to the Investors a certificate representing the Shares being purchased thereby and Warrants. 

 2. Representations and Warranties of the Company. The Company hereby represents and warrants to
the Investors that, except as set forth in the Company SEC Documents (as defined herein): 
  
 2.1 Organization and Standing. The Company is a corporation duly organized and validly existing under the laws of the State of Delaware and is in good standing under such laws. The Company has all requisite
corporate power to own and operate its properties and assets, and to carry on its business as presently conducted. The Company is qualified to do business as a foreign corporation in the State of California. Such qualification is not presently
required in any other jurisdiction where a failure to so qualify would have a material adverse effect on the Company. 
  
 2.2 Capitalization. The authorized capital stock of the Company consists of 50,000,000 shares of Common Stock and 5,000,000 shares of preferred
stock, of which 24,819,374 shares of Common Stock were issued and outstanding as of February 28, 2005. No shares of preferred stock are issued and outstanding. All such issued and outstanding shares have been duly authorized and validly issued and
are fully paid and nonassessable. As of February 28, 2005, the Company has reserved 214,980 shares of Common Stock for issuance upon the exercise of stock options granted under the Company’s 1997 Stock Option Plan, no shares are available for
future grant under the Company’s 1997 Stock Option Plan, 3,206,446 shares of Common Stock for issuance upon the exercise of stock options granted under the Company’s 2000 Stock Option Plan, and 3,110,860 shares of Common Stock are
available for future grant under the 2000 Stock Option Plan, and 975,975 shares of Common Stock are available for purchase under the Company’s 2000 Employee Stock Purchase Plan, and 1,474,542 shares of Common Stock for issuance upon the
exercise of outstanding warrants to purchase Common Stock (without giving effect to any dilution adjustments to outstanding warrants as a consequence of the transactions herein). Except as disclosed in the Company SEC Documents (as defined below),
there are no other options, warrants, conversion privileges, or preemptive or other rights or agreements presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the capital stock or other securities of the
Company. 
  
 2.3 Authority. The Company has full corporate
power and authority to execute and deliver this Agreement, and to consummate the transactions contemplated by this Agreement. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the execution and
delivery of, and the consummation of the transactions contemplated by this Agreement and the performance of all obligations of the Company under this Agreement, has been taken. This Agreement, upon execution and delivery by the Company and assuming
the due and proper execution and delivery by Investor, constitutes a legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or
other laws of general application relating to or affecting the enforcement of creditors rights generally, and (ii) the effect of rules of law governing the availability of equitable remedies. 
  
 2.4 Valid Issuance of Common Stock. The First Closing Shares to be
sold hereby has been duly authorized and, when issued, delivered and paid for in the manner set forth in this Agreement, will be duly authorized, validly issued, fully paid and nonassessable, and will be free of restrictions on transfer other than
restrictions on transfer under this Agreement and under applicable state and federal securities laws. Except for the preemptive rights granted by the Company pursuant to that certain Securities Purchase Agreement dated February 4, 2004 by and among
the Company and certain investors thereto, the issuance and sale by the Company of the First Closing Shares and the Second Closing Shares pursuant to this Agreement are not subject to any preemptive or other 

  

 -2- 

 
subscription or purchase rights of any Person. For purposes of this Agreement, “Person” shall mean an individual, a corporation, a partnership
(general or limited), a joint venture, an association, an organization, a trust or any other entity. 
  
 2.5 Governmental Consents. No registration, authorization, approval, qualification or consent of any court or governmental authority or agency or
self-regulatory organization, including the NASD, is necessary in connection with the execution and delivery of this Agreement or the offering, issuance or sale of the Shares under this Agreement, except (i) exemptive filings under applicable
securities laws which are not required to be made until after the First Closing and (ii) the registration of the Shares as set forth below. 
  
 2.6 No Conflicts. The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions
contemplated thereby in accordance with their respective terms do not and will not (i) conflict with or violate any provision of the Company’s or any subsidiary’s certificate or articles of incorporation, bylaws or other organizational or
charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or subsidiary debt or otherwise) or other understanding to which the Company or any subsidiary is a party or by which any
property or asset of the Company or any subsidiary is bound or affected, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the
Company or a subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as
could not, individually or in the aggregate, have or reasonably be expected to result in a material adverse effect. 
  
 2.7 SEC Documents; Material Contracts; Financial Statements. The Company has filed all documents required to be filed under the Exchange Act of
1934, as amended (the “1934 Act”). The information contained in (a) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004, the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended
March 31, 2004, June 30, 2004, and September 30, 2004 and (b) the Company’s Proxy Statement for its 2004 Annual Meeting of Stockholders (together, the “Company SEC Documents”), is true and correct in all material respects as of their
respective dates. The financial statements of the Company included in the Company SEC Documents (the “Financial Statements”) comply as to form in all material respects with applicable accounting requirements and with the published rules
and regulations of the Securities and Exchange Commission (the “SEC”) with respect thereto. The Financial Statements have been prepared in accordance with generally accepted accounting principles consistently applied and fairly present the
consolidated financial position of the Company and any subsidiaries at the dates thereof and the consolidated results of operations and consolidated cash flows for the periods then ended (subject, in the case of any unaudited financial statements,
to normal, recurring adjustments). 
  
 2.8 Litigation.
There is no pending or threatened lawsuit, administrative proceeding, arbitration, labor dispute or governmental investigation (“Litigation”) to which the Company is a party or by which any material portion of its assets, taken as a whole,
may be bound and which Litigation, if adversely determined, would have a material adverse effect on the Company’s assets, liabilities, financial condition or operations. 
  

 -3- 

 2.9 Material Changes. Since the date of the latest audited financial statements included within
the SEC Documents, except as specifically disclosed in the SEC Documents, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a material adverse effect, (ii) the Company has not
incurred any liabilities (contingent or otherwise) other than (A) trade payables, accrued expenses and other liabilities incurred in the ordinary course of business consistent with past practice and (B) liabilities (not to exceed $50,000) not
required to be reflected in the Company’s financial statements pursuant to United States generally accepting accounting principles or required to be disclosed in filings made with the SEC, (iii) the Company has not altered its method of
accounting or the identity of its auditors, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its
capital stock and (v) the Company has not issued any equity securities to any officer, director or affiliate, except pursuant to existing Company stock option plans and consistent with past practice. The Company does not have pending before the SEC
any request for confidential treatment of information. 
  
 2.10
Labor Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company. 
  

2.11 Compliance. Neither the Company nor any subsidiary (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any subsidiary under), nor has the Company or any subsidiary received notice of a claim that it is in default under or that it is in violation of, any
indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any
court, arbitrator or governmental body, or (iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not, individually or in the aggregate, have or reasonably be expected to result in a material adverse effect. The
Company is in compliance with all effective requirements of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations thereunder, that are applicable to it, except where such noncompliance could not have or reasonably be expected to
result in a material adverse effect. 
  
 2.12 Regulatory
Permits. The Company and the subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Documents, except where the failure to possess such permits could not, individually or in the aggregate, have or reasonably be expected to result in a material adverse effect, and neither the Company nor any subsidiary has received any notice of
proceedings relating to the revocation or modification of any such permits. 
  

 -4- 

 2.13 Title to Assets. The Company and the subsidiaries have good and marketable title in fee
simple to all real property owned by them that is material to their respective businesses and good and valid title in all personal property owned by them that is material to their respective businesses, in each case free and clear of all liens,
except for liens that do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the subsidiaries. Any real property and facilities held under
lease by the Company and the subsidiaries are held by them under valid, subsisting and enforceable leases of which the Company and the subsidiaries are in compliance, except as could not, individually or in the aggregate, have or reasonably be
expected to result in a material adverse effect. 
  
 2.14
Patents and Trademarks. The Company and the subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses and other similar rights that are
necessary or material for use in connection with their respective businesses as described in the SEC Documents and which the failure to so have could, individually or in the aggregate, have or reasonably be expected to result in a material adverse
effect (collectively, the “Intellectual Property Rights”). To the knowledge of the Company, neither the Company nor any subsidiary has received a written notice that the Intellectual Property Rights used by the Company or any subsidiary
violates or infringes upon the rights of any person. Except as set forth in the SEC Documents, to the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another person of any of
the Intellectual Property Rights. 
  
 2.15 Insurance. The
Company and the subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company in its reasonable judgment deems appropriate. The Company has no reason to believe that it
will not be able to renew its and the subsidiaries’ existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business on terms consistent with market
for the Company’s and such subsidiaries’ respective lines of business. 
  
 2.16 Transactions With Affiliates and Employees. Except as set forth in the SEC Documents, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the
Company is presently a party to any transaction with the Company or any subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee
has a substantial interest or is an officer, director, trustee or partner. 
  
 2.17 Internal Accounting Controls. The Company and the subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with United States generally accepted accounting principles and to maintain asset
accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and 

  

 -5- 

 
appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as defined in the 1934 Act Rules
13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its subsidiaries, is made known to the certifying officers by others within those
entities, particularly during the period in which the Company’s Form 10-K or 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures in
accordance with Item 307 of Regulation S-K under the 1934 Act for the Company’s most recently ended fiscal quarter or fiscal year-end (such date, the “Evaluation Date”). The Company presented in its most recently filed Form 10-K or
Form 10-Q the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the Company’s
internal controls that would be required to be disclosed pursuant to Item 308(c) of Regulation S-K under the 1934 Act or, to the Company’s knowledge, in other factors that could reasonably be expected to have a material adverse effect on the
Company’s internal controls. 
  
 2.18 Certain Registration
Matters. Assuming the accuracy of the Investors’ representations and warranties set forth in Section 3, no registration under the Act is required for the offer, sale and issuance of the Securities by the Company to the Investors under this
Agreement. Except as disclosed in the SEC Documents, the Company has not granted or agreed to grant to any person any rights (including “piggy back” registration rights) to have any securities of the Company registered with the SEC or any
other governmental authority that have not been satisfied or exercised. 
  
 2.19 No Additional Agreements. The Company does not have any agreement or understanding with any Investor with respect to the transactions contemplated by this Agreement other than as specified in this Agreement. 
  
 2.20 Disclosure. The Company confirms that neither it nor any person
acting on its behalf has provided any Investor or its respective agents or counsel with any information that the Company believes constitutes material, non-public information except insofar as the existence and terms of the proposed transactions
hereunder may constitute such information. The Company understands and confirms that the Investors will rely on the foregoing representations and covenants in effecting transactions in securities of the Company. All disclosure provided to the
Investors regarding the Company, its business and the transactions contemplated hereby, furnished by or on behalf of the Company (including the Company’s representations and warranties set forth in this Agreement) are true and correct in all
material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.

  
 3. Representations, Warranties and Covenants of the
Investors. Each investor hereby represents, warrants, and covenants that: 
  
 3.1 Authorization. Such Investor has full power and authority to execute and deliver, and to consummate the transactions contemplated by the Closing and this Agreement. All corporate action on the part of such
Investor, its officers, directors and stockholders necessary for 

  

 -6- 

 
(i) the execution and delivery of, and the consummation of the transactions contemplated by, this Agreement, and (ii) as of the First Closing, the
performance of all obligations of such Investor under this Agreement, has been taken. This Agreement, upon execution and delivery by such Investor and assuming the due and proper execution and delivery by the Company, constitutes a legal, valid and
binding obligation of such Investor, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of
creditors rights generally, and (ii) the effect of rules of law governing the availability of equitable remedies. 
  
 3.2 Purchase Entirely for Own Account. Such Investor represents that the Securities will be acquired for investment for such Investor’s own
account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing
this Agreement, such Investor further represents that Investor does not have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of
the Securities. 
  
 3.3 Disclosure of Information. Such
Investor has received all information it considers necessary or appropriate for deciding whether to purchase the Common Stock. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of the Common Stock and the business, properties, prospects and financial condition of the Company. 
  
 3.4 Investment Experience. Such Investor is an investor in securities of companies in the development stage and acknowledges that it is able to
appropriately identify the inherent risks associated with, and can bear the economic risk of the total lost of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and
risks of the investment in the Securities. Such Investor has not been organized for the purpose of acquiring the Securities. 
  
 3.5 Accredited Investor. Such Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D, as presently in
effect. 
  
 3.6 Restricted Securities. Such Investor
understands that the Securities it is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that
under such laws and applicable regulations such securities may be resold without registration under the Securities Act of 1933, as amended (the “Act”), only in certain limited circumstances. In this connection, Investor represents that it
is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Act. 
  
 3.7 Further Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor further agrees not to make
any disposition of all or any portion of the Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this section provided and to the extent this section is applicable, and: 
  
 (a) There is then in effect a registration statement under the Act covering
such proposed disposition and such disposition is made in accordance with such registration statement; or 
  

 -7- 

 (b) If reasonably requested by the Company, such Investor shall have furnished the Company with an
opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule
144 except in unusual circumstances. 
  
 Each Investor agrees that
it will promptly notify the Company of any material changes in the information set forth in the Registration Statement regarding the Investor or its plan of distribution. 
  
 3.8 Additional Trading Limitations. Such Investor has not directly or indirectly, nor has any Person acting on behalf
of or pursuant to any understanding with such Investor, engaged in any transactions in the securities of the Company (including, without limitations, any Short Sales involving the Company’s securities) since the earlier to occur of (1) the time
that such Investor was first contacted by the Company or any other Person regarding an investment in the Company and (2) the 20th day prior to the public announcement of the transactions contemplated by this Agreement. Such Investor covenants that neither it nor any Person acting on its behalf or pursuant to any understanding with it will engage in any
transactions in the securities of the Company (including Short Sales) prior to the time that the transactions contemplated by this Agreement are publicly disclosed. For purposes of this section, a “Short Sale” includes, without limitation,
all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar arrangements (including on
a total return basis), and sales and other transactions through non-US broker dealers or foreign regulated brokers. 
  
 3.9 Legends. Each certificate or instrument representing Shares shall bear legends in substantially the following forms: 
  
 (i) “THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ‘SECURITIES ACT’) AND ARE ‘RESTRICTED SECURITIES’ AS DEFINED IN RULE 144 PROMULGATED UNDER THE SECURITIES ACT. THE SECURITIES MAY NOT BE SOLD OR OFFERED
FOR SALE OR OTHERWISE DISTRIBUTED EXCEPT (I) IN CONJUNCTION WITH AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, OR (II) IN COMPLIANCE WITH RULE 144, OR (III) PURSUANT TO AN OPINION OF COUNSEL SATISFACTORY TO THE
ISSUER OF THESE SECURITIES THAT SUCH REGISTRATION OR COMPLIANCE IS NOT REQUIRED AS TO SUCH SALE, OFFER OR DISTRIBUTION.” 
  
 (ii) Any other legends required by California law or other applicable blue sky or state securities laws. 
  

 -8- 

 The Company need not register a transfer of any Shares, and may also instruct its transfer agent not to register a
transfer of any Shares, unless the conditions specified in the foregoing legends are satisfied to the extent applicable. 
  
 4. Registration Procedures and Expenses. 
  
 4.1 Obligations of the Company. Subject to the receipt of all necessary information from all of the Investors, the Company shall: 
  
 (a) use its commercially reasonable efforts to prepare and file with the
SEC, within 30 business days after the First Closing (the “Required Filing Date”), a registration statement to enable the resale of the Shares and Warrant Shares acquired or to be acquired pursuant to this Agreement by the Investors (the
“Registration Statement”); provided, however, that the Company may defer filing the Registration Statement to ensure compliance with Rule 3-12 of Regulation S-X; 
  
 (b) use its commercially reasonable efforts to cause the Registration Statement to become effective as soon as practicable,
but in no event later than ninety (90) days after the date of the First Closing, or one hundred and twenty (120) days after the date of the First Closing in the event the Registration Statement is reviewed by the SEC (as applicable, the
“Required Effective Date”); 
  
 (c) make compensatory
payments to the Investor in the event the Registration Statement has not been declared effective by the SEC after the Required Effective Date (each payment, a “Late Registration Payment”), provided however, that no further Late
Registration Payments shall accrue once the Registration Statement has been initially declared effective by the SEC; each Late Registration Payment is (1) equal to 1% of the Purchase Price paid for the Shares (it being understood that in no event
shall any payment hereunder accrue as to the Warrants or the Warrant Shares) purchased by the Investor and not previously sold by the Investor for each 30 day period after the Required Effective Date, pro rated by the number of days elapsed in the
applicable 30 day Late Registration Payment period, and (2) payable to the Investor by wire transfer or check within five business days after the earlier of (i) the end of each 30 day period following the Required Effective Date or (ii) the
effective date of the Registration Statement; 
  
 (d) keep such
Registration Statement effective for a period of up to two years, or such lesser period of time as all of the Shares have been sold or can be sold without restriction under Rule 144; 
  
 (e) prepare and file with the SEC such amendments and supplements to such Registration Statement and the prospectus used in
connection with such Registration Statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such Registration Statement; 
  
 (f) furnish to each Investor such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of securities; 
  

 -9- 

 (g) use commercially reasonable efforts to register and qualify the securities covered by such
Registration Statement under such other securities or Blue Sky laws of such jurisdictions as shall be requested by each Investor; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do
business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Act; and 
  
 (h) cause all such securities registered pursuant hereunder to be listed,
prior to the date of the first sale of such securities pursuant to such registration, on each securities exchange on which similar securities issued by the Company are then listed. 
  
 4.2 Additional Registration Statements. If for any reason (i) the SEC does not permit all of the Shares and Warrant
Shares to be included in the Registration Statement filed pursuant to Section 4.1(a), or (ii) any outstanding Shares and Warrant Shares (without regard to any exercise caps contained in the Warrants) are not then covered by an effective Registration
Statement, then in each such case the Company shall prepare and file within 30 days of realizing such obligation, an additional Registration Statement covering the resale of all such outstanding and issuable Shares and Warrant Shares not already
covered by an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415, on Form S-3 (or other appropriate form for such purpose). The Company shall cause each such Registration Statement to
be declared effective under the Act as soon as possible but, in any event, within 120 days of realizing its obligation to file such Registration Statement, and shall use its reasonable best efforts to keep such Registration Statement continuously
effective under the Act. 
  
 Not less than four trading days prior
to the filing of a Registration Statement or any related prospectus or any amendment or supplement thereto, the Company shall furnish to each holder of Shares or Warrant Shares copies of the “Selling Stockholders” section of such document,
the “Plan of Distribution” and any risk factor contained in such document that addresses specifically this transaction or the Selling Stockholders, as proposed to be filed, which documents will be subject to the review of such holder. The
Company shall not file a Registration Statement, any prospectus or any amendments or supplements thereto in which the “Selling Stockholder” section thereof differs from the disclosure received from a holder in its Selling Holder
Questionnaire (as amended or supplemented). 
  
 The Company shall
use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification)
of any of the Shares or Warrant Shares for sale in any jurisdiction, at the earliest practicable moment. 
  
 Upon notification by the SEC that a Registration Statement will not be reviewed or is no longer subject to further review and comments, the Company shall
request acceleration of such Registration Statement such that it becomes effective at 5:00 p.m. (New York City time) on the date such Registration Statement is declared effective. 
  
 Deliver to each Investor, by 9:00 a.m. (New York City time) on the day following the date such Registration Statement is
declared effective, without charge, an electronic copy of each 

  

 -10- 

 
prospectus or prospectuses (including each form of prospectus) and each amendment or supplement thereto. The Company hereby consents to the use of such
prospectus and each amendment or supplement thereto by each of the selling holders in connection with the offering and sale of the Shares and Warrant Shares covered by such prospectus and any amendment or supplement thereto. 
  
 4.3 Suspension of Prospectus. Each Investor acknowledges that there
may occasionally be times when the Company determines, in good faith following consultation with its board of directors or a committee thereof, the use of the prospectus forming a part of the Registration Statement (the “Prospectus”)
should be suspended until such time as an amendment or supplement to the Registration Statement or the Prospectus has been filed by the Company and any such amendment to the Registration Statement is declared effective by the Commission, or until
such time as the Company has filed an appropriate report with the Commission pursuant to the 1934 Act, provided that the Company shall use commercially reasonable efforts to lift such suspension. Each Investor hereby covenants that it will not sell
any Shares or Warrant Shares pursuant to the Prospectus during the period commencing at the time at which the Company gives the Investor written notice of the suspension of the use of the Prospectus and ending at the time the Company gives the
Investor written notice that the Investor may thereafter effect sales pursuant to the Prospectus. The Company may, upon written notice to the Investors, suspend the use of the Prospectus for no more than sixty (60) days in the aggregate; and
provided further that no suspension shall occur until at least ten (10) trading days after the expiration of any previous suspension. The Company shall in no event be required to disclose the business purpose for which it has suspended the use of
the Prospectus if the Company determines in its good faith judgment that the business purpose should remain confidential. Each Investor covenants to notify the Company promptly of the sale of any of its Shares or Warrant Shares, other than sales
pursuant to the Registration Statement or sales upon termination of the transfer restrictions herein. Should the Company suspend the use of the Prospectus for more than sixty (60) days in the aggregate, the Company shall make compensatory payments
to the Investor (each payment, a “Suspension Payment”), each Suspension Payment is (1) equal to 1% of the Purchase Price paid for the Shares (it being understood that in no event shall any payment hereunder accrue as to the Warrants or the
Warrant Shares) purchased by the Investor and not previously sold by the Investor for each 30 day period during which the use of the Prospectus was suspended, pro rated by the number of days elapsed in the applicable 30 day period, and (2) payable
to the Investor by wire transfer or check within five business days after the earlier of (i) the end of each 30 day period or (ii) the lifting of each suspension. 
  
 4.4 Re-Register on Form S-3. For two years after the date of the First Closing, to the extent the registration of the
Shares and Warrant Shares pursuant to Section 4.1 is not made on Form S-3, the Company shall use reasonable efforts re-register the Shares and Warrant Shares on Form S-3 when the Company becomes eligible to register such Shares and Warrant Shares
thereon. 
  
 4.5 Expenses of Registration. The Company
shall pay all expenses in connection with the registration of the Shares and Warrant Shares pursuant to Section 4.1, provided however, that the Company shall not pay any fees and expenses of any counsel or advisors to the Investors or brokerage fees
and commissions incurred by them. 
  
 4.6 Furnishing of
Information. As long as any Investor owns the Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the 

  

 -11- 

 
applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the 1934 Act. As long as any Investor owns
Securities, if the Company is not required to file reports pursuant to such laws, it will prepare and furnish to the Investors and make publicly available in accordance with Rule 144(c) such information as is required for the Investors to sell the
Shares and Warrant Shares under Rule 144. The Company further covenants that it will take such further action as any holder of Securities may reasonably request, all to the extent required from time to time to enable such person to sell the Shares
and Warrant Shares without registration under the Act within the limitation of the exemptions provided by Rule 144. 
  
 4.7 Integration. Subject to Section 8 herein, the Company shall not, and shall use its best efforts to ensure that no affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Act) that would be integrated with the offer or sale of the Securities in a manner that would require the
registration under the Act of the sale of the Securities to the Investors, or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any trading market in a manner that would require
stockholder approval of the sale of the Securities to the Investors. 
  
 4.8 Subsequent Registrations. Prior to the date the SEC declares the Registration Statement effective, the Company may not file any registration statement with the SEC with respect to any securities of the Company other than
registration statements on Form S-4 or Form S-8 promulgated by the SEC. 
  
 4.9 No Piggyback on Registrations. Neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in a Registration Statement other than the Shares
and Warrant Shares, and the Company shall not during the period the Registration Statement is required to be effective enter into any agreement providing any such right to any of its security holders. 
  
 4.10 Piggyback Registrations. If at any time during the period the
Registration Statement is required to be effective there is not an effective Registration Statement covering all of the Shares and Warrant Shares and the Company shall determine to prepare and file with the SEC a registration statement relating to
an offering for its own account or the account of others under the Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Act) or their then equivalents relating to equity securities to be issued
solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Company shall send to each holder written notice of such determination and,
if within fifteen days after receipt of such notice, any such holder shall so request in writing, the Company shall include in such registration statement all or any part of such Shares and Warrant Shares such holder requests to be registered,
subject to customary underwriter cutbacks applicable to all holders of registration rights. 
  
 4.11 Securities Laws Disclosure; Publicity. By 9:00 a.m. (New York City time) on the trading day following the execution of this Agreement, and by 9:00 a.m. (New York City time) on the trading day following
each of the First Closing and Second Closing, the Company shall issue press releases in forms approved by the Investors disclosing the transactions contemplated hereby. On the Trading Day following the execution of this Agreement the Company will
file a Current 

  

 -12- 

 
Report on Form 8-K disclosing the material terms of this Agreement (and attach as exhibits thereto this Agreement and the Warrant), and on the Trading Day
following each of the First Closing and Second Closing the Company will file additional Current Reports on Form 8-K to disclose the First Closing and Second Closing. In addition, the Company will make such other filings and notices in the manner and
time required by the SEC and the trading market on which the Common Stock is listed. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Investor, or include the name of any Investor in any filing with the SEC
(other than the Registration Statement and any exhibits to filings made in respect of this transaction in accordance with periodic filing requirements under the 1934 Act) or any regulatory agency or trading market, without the prior written consent
of such Investor, except to the extent such disclosure is required by law or trading market regulations. 
  
 4.12 Non-Public Information. The Company covenants and agrees that neither it nor any other person acting on its behalf will provide any Investor
or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto such Investor shall have executed a written agreement regarding the confidentiality and use of such
information. 
  
 4.13 Replacement of Securities. If any
certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new
certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation thereof, the
Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 
  
 4.14 Indemnification. In connection with the Registration Statement required to be filed by the Company pursuant to this Section 4: 
  
 (a) To the extent permitted by law, the Company will indemnify and hold
harmless each Investor, the officers, directors and partners of each Investor and each Person, if any, who controls any thereof within the meaning of the Act or the 1934 Act, against any losses, claims, damages, or liabilities (joint or several) to
which they may become subject under the Act or the 1934 Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following (collectively a
“Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Act, the
1934 Act, any state securities law or any rule or regulation promulgated under the Act, or the 1934 Act or any state securities law; and the Company will pay to each Investor or controlling Person, as incurred, any legal or other expenses reasonably
incurred by them in connection with investigating or defending any such loss, 

  

 -13- 

 
claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this subsection 4.3(a) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case to the extent any
such loss, claim, damage, liability or action arises out of or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished to the Company in an instrument duly executed by such Investor, officer,
director, partner or controlling Person expressly for use in connection with such registration. 
  
 (b) To the extent permitted by law, each selling Investor will indemnify and hold harmless the Company, each of its directors, each of its officers who
has signed the Registration Statement, each Person, if any, who controls the Company within the meaning of the Act, against any losses, claims, damages, or liabilities (joint or several) to which any of the foregoing Persons may become subject,
under the Act, or the 1934 Act or other federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent)
that such Violation occurs in reliance upon and in conformity with written information furnished to the Company in an instrument duly executed by such Investor expressly for use in connection with such registration; and each Investor will pay, as
incurred, any legal or other expenses reasonably incurred by any Person intended to be indemnified pursuant to this Section 4.3(b), in connection with investigating or defending any such loss, claim, damage, liability, or action; provided, however,
that the indemnity agreement contained in this Section 4.3(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of such Investor, which consent shall
not be unreasonably withheld; provided, that, in no event shall any indemnity under this Section 4.3(b) exceed the net proceeds from the offering received by such Investor. 
  
 (c) Promptly after receipt by an indemnified party under this Section 4.3 of notice of the commencement of any action
(including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 4.3, deliver to the indemnifying party a written notice of the commencement thereof and
the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the
parties; provided, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid
by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party
represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section 4.3, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise
than under this Section 4.3. 
  

 -14- 

 (d) If the indemnification provided for in this Section 4.3 is held by a court of competent jurisdiction
to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid
or payable by such indemnified party as a result of such loss, liability, claim, damage, or expense (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of
the indemnified party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense (or actions in respect thereof) as well as any other relevant equitable considerations. The relative
fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. The Company and each Investor agree that it
would not be just and equitable if contribution pursuant to this Agreement were determined by pro-rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above. The amount paid or
payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above shall include any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. 
  
 (e) The
obligations of the Company and Investor under this Section 4.3 shall survive the completion of any offering of securities in a Registration Statement under this Section 4, and otherwise. 
  
 4.15 Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under this
Agreement and its Warrants are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under the Agreement or its Warrants. The
decision of each Investor to purchase Securities pursuant to this Agreement has been made by such Investor independently of any other Investor. Nothing contained herein, and no action taken by any Investor pursuant thereto, shall be deemed to
constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by this Agreement. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection
with monitoring its investment in the Securities or enforcing its rights under this Agreement or their Warrant. Each Investor shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of
this Agreement or out of its Warrants, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same
Agreement and form of Warrant for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. 
  
 4.16 Limitation of Liability. Notwithstanding anything herein to the contrary, the Company acknowledges and agrees
that the liability of an Investor arising directly or indirectly, 

  

 -15- 

 
under this Agreement or its Warrants of any and every nature whatsoever shall be satisfied solely out of the assets of such Investor, and that no trustee,
officer, other investment vehicle or any other affiliate of such Investor or any investor, shareholder or holder of shares of beneficial interest of such a Investor shall be personally liable for any liabilities of such Investor. 
  
 5. Conditions of Each Investor’s Obligations at the First
Closing. The obligations of each Investor to accept delivery of the First Closing Shares and the First Closing Warrants and to make payments therefor are subject to the fulfillment on or before the First Closing of each of the following
conditions, any one or more of which may be waived by an Investor with respect to such Investor’s obligation: 
  
 5.1 Representations and Warranties. The representations and warranties of the Company contained in Section 2 shall be true on and as of the First
Closing with the same effect as though such representations and warranties had been made on and as of the date of the First Closing. 
  
 5.2 Performance. The Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are
required to be performed or complied with by it on or before the First Closing. 
  
 5.3 Proceedings and Documents. All corporate and other proceedings in connection with the transactions contemplated herein and all documents incident thereto shall be reasonably satisfactory in form and
substance to Investor, and it shall have received all such counterpart original and certified or other copies of such documents as it may reasonably request. 
  
 5.4 Opinion of Company Counsel. The Investors shall have received an opinion from counsel to the Company in form and substance reasonably
satisfactory to the counsel to SF Capital Partners Ltd. 
  
 5.5
Escrow Agreement. The Company shall have executed and delivered the Escrow Agreement in substantially the form attached hereto as Exhibit B. 
  
 6. Conditions of the Company’s Obligations at the First Closing. The obligations of the Company to sell and issue the First Closing Shares and
the First Closing Warrants are subject to the fulfillment on or before the First Closing of each of the following conditions by each Investor, any one or more of which may be waived by the Company: 
  
 6.1 Representations and Warranties. The representations and
warranties of Investors contained in Section 3 shall be true on and as of the First Closing with the same effect as though such representations and warranties had been made on and as of the First Closing. 
  
 6.2 Payment of First Closing Purchase Price. The receipt of same-day
funds in the full amount of the purchase price for the First Closing Shares by the Escrow Agent as specified in Section 1. The Escrow Agent’s wire instructions are attached hereto as Schedule II. 
  
 6.3 Payment of Second Closing Escrow Funds. The deposit of same-day
funds in the full amount of the purchase price for the Second Closing Shares with the Escrow Agent as specified in Section 1. 
  

 -16- 

 6.4 Escrow Agreement. Each Investor shall have executed and delivered the Escrow Agreement in
substantially the form attached hereto as Exhibit B. 
  
 7.
Conditions to The Second Closing. The obligations of each Investor to accept delivery of and to make payments for, and the Company’s obligation to sell and issue, the Second Closing Shares and the Second Closing Warrants are subject to
(i) the Company’s receipt of stockholder approval for the issuance of the Second Closing Shares and the Second Closing Warrants as may be required pursuant to the rules of the Nasdaq Stock Market (the “Stockholder Approval
Condition”); and (ii) the Company’s receipt of stockholder approval for the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock by an amount
sufficient to issue the Securities to be issued in the Second Closing (the “Certificate Amendment”); and (iii) evidence of the filing of the Certificate Amendment with the Delaware Secretary of State; and (iv) receipt by the Investors of
an opinion from counsel to the Company in substantially the form attached hereto as Exhibit C. Upon the satisfaction of the foregoing conditions, (i) the Company will issue to the Investors the Second Closing Shares and Second Closing Warrants; and
(ii) the Escrow Agent shall promptly release the Escrowed Funds to the Company consistent with the terms of the Escrow Agreement, and any interest on the Escrowed Funds shall be returned by the Escrow Agent to the Investors. If the Stockholder
Approval Condition is not satisfied by June 30, 2005, then the funds deposited with the Escrow Agent for the Second Closing shall be returned to the Investors in the manner specified in the Escrow Agreement. 
  
 8. Stockholder Approval Event. The Company is required to seek the
stockholder approval in satisfaction of the Stockholder Approval Condition within 45 days of the date of the First Closing (the “Stockholder Approval Termination Date”). The Stockholder Approval Termination Date may be extended by the
Company without notice to the Investors for up to an additional 30 days. If Stockholder Approval is not obtained by the Stockholder Approval Termination Date, as extended as provided herein, then the obligation of the Investors to purchase
Securities in the Second Closing will be terminable at the option of the Investor, and if terminated, such obligations of the Investor to purchase Securities in the Second Closing shall be deemed null and void. In addition, in the event Stockholder
Approval Condition has not been satisfied by the Company on or before the Stockholder Approval Termination Date (as may be extended by the Company), the Company will release the Investors funds from escrow and have the full amount of such funds
returned to Investor. 
  
 9. Offering Termination Date.
Unless terminated earlier in the Company’s sole discretion, the offering herein will expire on the earlier to occur of the Second Closing Date or 11:59 p.m. New York city time on June 30, 2005. 
  
 10. Miscellaneous. 
  
 10.1 Survival of Warranties. The warranties, representations and
covenants of the Company and Investor contained in or made pursuant to this Agreement shall survive for two years after the execution and delivery of this Agreement. 
  
 10.2 Assignment; Successors and Assigns. No provision of this Agreement may be assigned by any Investor without the
prior written consent of the Company which shall not be 

  

 -17- 

 
unreasonably withheld. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  

10.3 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among
California residents entered into and to be performed entirely within California. 
  
 10.4 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 10.5 Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 10.6 Notices, etc. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by personal delivery,
facsimile, overnight courier or mailed by certified or registered mail, postage prepaid, return receipt requested, to the facsimile number or address as follows: 
  
 Company: 
  
 Curon Medical, Inc. 
 46117 Landing Parkway

 Fremont, CA 94538-6407 
 Facsimile: (510) 661-1899 
 Attention: President 
  
 with a copy to: 
  
 Wilson Sonsini Goodrich & Rosati, P.C. 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Facsimile: (650) 493-6811 
 Attention: David J. Saul 
  
 Investors: 
  
 To the facsimile number or address for each respective Investor set forth in Schedule I hereto. 
  
 Placement Agent: 
  
 SVB Alliant 
 181 Lytton Avenue 
 Palo Alto, CA 94301

 Facsimile: (650) 330-3010 
 Attention: Jeff Berry 
  

 -18- 

 And its sub-agent 
  
 The Robins Group LLC 
 3220 SW First Ave 
 Suite 201 
 Portland, OR 97239 
 Facsimile: (503) 445-2490 
 Attention: Marcus W. Robins 
  
 or to such other
facsimile number or address provided to the parties to this Agreement in accordance with this Section 7.6. Such notices or other communications shall be deemed delivered upon receipt, in the case of overnight delivery, personal delivery or facsimile
transmission (as evidenced by the confirmation thereof), or 3 days after deposit in the mails (as determined by reference to the postmark). 
  
 10.7 Finder’s Fee. Except for SVB Alliant and The Robins Group LLC, no Person has, or as a result of the transactions contemplated herein will
have, any right or valid claim against the Company or the Investor for any commission, fee or other compensation as a finder or broker, or in any similar capacity based upon obligations incurred by the Company. Notwithstanding the foregoing, at the
First Closing, the Company shall reimburse SF Capital Partners Ltd. $20,000 in connection with its legal fees concerning the transactions contemplated by the Transaction Documents (SF Capital Partners Ltd. may deduct such amount from the portion of
its investment amount deliverable to the Company at the First Closing), it being understood that Bryan Cave LLP has only rendered legal advice to SF Capital Partners Ltd., and not to the Company or any Investor in connection with the transactions
contemplated hereby, and that each of the Company and each Investor has relied for such matters on the advice of its own respective counsel. 
  
 10.8 Expenses. Irrespective of whether any Closing is effected, each party shall pay its own costs and expenses that it incurs with respect to the
negotiation, execution, delivery and performance of this Agreement. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees, costs
and necessary disbursements in addition to any other relief to which such party may be entitled. 
  
 10.9 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and a majority in interest of the Investors. Any amendment or waiver effected in accordance with this paragraph shall be
binding upon each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities are convertible), each future holder of all such securities, and the Company. Each Investor
acknowledges and agrees that a majority in interest may effect any amendment or waiver hereunder adverse to their interests. 
  

 -19- 

 10.10 Severability. If one or more provisions of this Agreement are held to be unenforceable under
applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 
  
 10.11 Entire Agreement. This Agreement and the documents referred to
herein constitute the entire agreement among the parties and no party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically set forth herein or therein. 
  
 [Signature Page Follows] 
  

 -20- 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	 COMPANY:

	
	 CURON MEDICAL, INC.

		
	 By:
	 	 /s/ Larry C. Heaton II

	 	 	 Larry Heaton

	 	 	 President and Chief Executive Officer

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 INVESTORS:

	
	 ATLAS EQUITY I, LTD

		
	 By:
	 	 /s/ Scott Schroeder

	 Name:
	 	 Scott Schroeder

	 Title:
	 	 Authorized Signatory

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 CIMARRON OVERSEAS EQUITY MASTER
 FUND L.P.

		
	 By:
	 	 /s/ J.H. Cullum Clark

	 Name:
	 	 J.H. Cullum Clark

	 Title:
	 	 General Partner for General Partner

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 CROWN GROWTH PARTNERS II

	 CROWN GROWTH PARTNERS, L.P.

		
	 By:
	 	 /s/ David F. Bellet

	 Name:
	 	 David F. Bellet

	 Title:
	 	 Chairman, Crown Advisors

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 HARVEST CAPITAL, LP

		
	 By:
	 	 /s/ James Morgan Rutman

	 Name:
	 	 James Morgan Rutman

	 Title:
	 	 Managing Member of Harvest
 Advisors, L.L.C. its General
 Partner

	
	 HARVEST OFFSHORE INVESTORS, LTD.

		
	 By:
	 	 /s/ James Morgan Rutman

	 Name:
	 	 James Morgan Rutman

	 Title:
	 	 Managing Member of Harvest
 Advisors, L.L.C. its General
 Partner

	
	 NEW AMERICANS, LLC

		
	 By:
	 	 /s/ James Morgan Rutman

	 Name:
	 	 James Morgan Rutman

	 Title:
	 	 Managing Member of Harvest
 Advisors, L.L.C. its General
 Partner

	
	 CL HARVEST, LLC

		
	 By:
	 	 /s/ James Morgan Rutman

	 Name:
	 	 James Morgan Rutman

	 Title:
	 	 Managing Member of Harvest
 Advisors, L.L.C. its General
 Partner

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 HARVEST AA CAPITAL, LP

		
	 By:
	 	 /s/ James Morgan Rutman

	 Name:
	 	 James Morgan Rutman

	 Title:
	 	 Managing Member of Harvest
 Advisors, L.L.C. its General
 Partner

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 LEWIS OPPORTUNITY FUND LP

		
	 By:
	 	 /s/ William A. Lewis IV

	 Name:
	 	 William A. Lewis IV

	 Title:
	 	 General Partner

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 MEADOWBROOK OPPORTUNITIES FUND, LLC

		
	 By:
	 	 /s/ Michael Ragins

	 Name:
	 	 Michael Ragins

	 Title:
	 	 Manager

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 MICRO CAP PARTNERS, L.P.

		
	 By:
	 	 /s/ William L. Edwards

	 Name:
	 	 William L. Edwards

	 Title:
	 	 General Partner

	
	 PALO ALTO HEALTHCARE FUND, L.P.

		
	 By:
	 	 /s/ William L. Edwards

	 Name:
	 	 William L. Edwards

	 Title:
	 	 General Partner

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 STROLLER TOD WHITE AND LINDA
 WHITE, TRUSTEES OF THE TOD & LINDA
 WHITE REVOCABLE TRUST, DATED
 5/21/98

		
	 By:
	 	 /s/ Jim Fitzpatrick

	 Name:
	 	 Jim Fitzpatrick

	 Title:
	 	 Attorney-in-fact

	
	 BRANCO WEISS

		
	 By:
	 	 /s/ Jim Fitzpatrick

	 Name:
	 	 Jim Fitzpatrick

	 Title:
	 	 Attorney-in-fact

	
	 WILLIAM H. REAVES - PCM

		
	 By:
	 	 /s/ Jim Fitzpatrick

	 Name:
	 	 Jim Fitzpatrick

	 Title:
	 	 Attorney-in-fact

	
	 YOUNG ENTERPRISE SECURITIES, LLC

		
	 By:
	 	 /s/ Jim Fitzpatrick

	 Name:
	 	 Jim Fitzpatrick

	 Title:
	 	 Attorney-in-fact

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 HUGH AND CONSTANCE FITZPATRICK

		
	 By:
	 	 /s/ Jim Fitzpatrick

	 Name:
	 	 Jim Fitzpatrick

	 Title:
	 	 Attorney-in-fact

	
	 NANCYE ALLEN FITZPATRICK

		
	 By:
	 	 /s/ Jim Fitzpatrick

	 Name:
	 	 Jim Fitzpatrick

	 Title:
	 	 Attorney-in-fact

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 PROMED PARTNERS, L.P.

	 PROMED PARTNERS II, L.P.

		
	 By:
	 	 /s/ Barry Kurokawa

	 Name:
	 	 Barry Kurokawa

	 Title:
	 	 Managing Director

	
	 PROMED OFFSHORE FUND, LTD.

	 PROMED OFFSHORE FUND II, LTD.

		
	 By:
	 	 /s/ Barry Kurokawa

	 Name:
	 	 Barry Kurokawa

	 Title:
	 	 Managing Director

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 SF CAPITAL PARTNERS LTD.

		
	 By:
	 	 /s/ Brian Stark

	 Name:
	 	 Brian Stark

	 Title:
	 	 Authorized Signatory

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 WALKER SMITH CAPITAL, L.P.

		
	 By:
	 	 WS Capital Management, L.P., General Partner

		
	 By:
	 	 WS Capital, L.L.C., General Partner

		
	 By:
	 	 /s/ Reid S. Walker

	 Name:
	 	 Reid S. Walker

	 Title:
	 	 Member

	
	 WALKER SMITH CAPITAL (QP), L.P.

		
	 By:
	 	 WS Capital Management, L.P., General Partner

		
	 By:
	 	 WS Capital, L.L.C., General Partner

		
	 By:
	 	 /s/ Reid S. Walker

	 Name:
	 	 Reid S. Walker

	 Title:
	 	 Member

	
	 WALKER SMITH INTERNATIONAL FUND, LTD.

		
	 By:
	 	 WS Capital Management, L.P., as agent and
 attorney-in-fact

		
	 By:
	 	 WS Capital, L.L.C., General Partner

		
	 By:
	 	 /s/ Reid S. Walker

	 Name:
	 	 Reid S. Walker

	 Title:
	 	 Member

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

			
	 SRB GREENWAY CAPITAL, L.P.

		
	 By:
	 	 SRB Management, L.P., General Partner

		
	 By:
	 	 BC Advisors, L.L.C., General Partner

		
	 By:
	 	 /s/ Steven R. Becker

	 Name:
	 	 Steven R. Becker

	 Title:
	 	 Member

	
	 SRB GREENWAY CAPITAL (QP), L.P.

		
	 By:
	 	 SRB Management, L.P., General Partner

		
	 By:
	 	 BC Advisors, L.L.C., General Partner

		
	 By:
	 	 /s/ Steven R. Becker

	 Name:
	 	 Steven R. Becker

	 Title:
	 	 Member

	
	 SRB GREENWAY OFFSHORE OPERATING
 FUND, L.P.

		
	 By:
	 	 SRB Management, L.P., General Partner

		
	 By:
	 	 BC Advisors, L.L.C., General Partner

		
	 By:
	 	 /s/ Steven R. Becker

	 Name:
	 	 Steven R. Becker

	 Title:
	 	 Member

  
 [Signature Page
to Curon Medical, Inc. Stock Purchase Agreement] 

 Schedule I 
  

Schedule of Investors 
  

															
	 Investor Name, Address and Fax Number

	  	First Closing
Purchase
Price

	  	First
Closing
Shares

	  	First
Closing
Warrants

	  	Second Closing
Purchase Price

	  	Second
Closing
Shares

	  	Second
Closing
Warrants

	 Atlas Equity I, LTD
 c/o Balyasny Asset Management LLC
 Scott Schroeder
 181 W. Madison
 Suite 3600
 Chicago, IL 60602
 Phone: 312-499-2999
 sschroeder@bam-us.com
	  	$	497,825.25	  	765,885	  	382,942	  	$	1,252,174.95	  	1,926,423	  	963,212
							
	 Cimarron Overseas Equity
 Master Fund
L.P.
 c/o Cimarron Biomedical Investors
 Rob Blakeney
 2626 Cole Avenue
 Suite 200
 Dallas, TX 75204
 Phone: 214-540-4802
 rblakeney@cimarronlp.com
	  	$	78,229.45	  	120,353	  	60,176	  	$	196,769.95	  	302,723	  	151,362
							
	 Crown Growth Partners II
 c/o Crown Advisors
 David Bellet
 The Lincoln Building
 60 East 42nd Street
 Suite 3405
 New York, NY 10165
 Phone: 212-808-5278
 bellet@crownadvisors.com
	  	$	3,272.75	  	5,035	  	2,517	  	$	8,232.25	  	12,665	  	6,333
							
	 Crown Growth Partners, L.P.
 c/o Crown Advisors
 David Bellet
 The Lincoln Building
 60 East 42nd Street
 Suite 3405
 New York, NY 10165
 Phone: 212-808-5278
 bellet@crownadvisors.com
	  	$	45,172.40	  	69,496	  	34,748	  	$	113,622.60	  	174,804	  	87,402

															
	 Harvest Capital, LP
 c/o Harvest Management LLC
 John Christ
 600 Madison Avenue; 11th Floor
 New York, NY 10022
 Phone: 212-634-3600
 Fax: 212-634-3636
 mr@harvestmgmt.com
 jc@harvestmgmt.com
	  	$	17,024.15	  	26,191	  	13,095	  	$	42,821.35	  	65,879	  	32,940
							
	 Harvest Offshore Investors, Ltd.
 c/o Harvest Management LLC
 John Christ
 600 Madison Avenue; 11th Floor
 New York, NY 10022
 Phone: 212-634-3600
 Fax: 212-634-3636
 mr@harvestmgmt.com
 jc@harvestmgmt.com
	  	$	43,707.95	  	67,243	  	33,621	  	$	109,939.05	  	169,137	  	84,569
							
	 New Americans, LLC
 c/o Harvest Management LLC
 John Christ
 600 Madison Avenue; 11th Floor
 New York, NY 10022
 Phone: 212-634-3600
 Fax: 212-634-3636
 mr@harvestmgmt.com
 jc@harvestmgmt.com
	  	$	4,956.90	  	7,626	  	3,813	  	$	12,469.60	  	19,184	  	9,592
							
	 CL Harvest, LLC
 c/o Harvest Management LLC
 John Christ
 600 Madison Avenue; 11th Floor
 New York, NY 10022
 Phone: 212-634-3600
 Fax: 212-634-3636
 mr@harvestmgmt.com
 jc@harvestmgmt.com
	  	$	1,889.55	  	2,907	  	1,453	  	$	4,753.45	  	7,313	  	3,657

															
	 Harvest AA Capital, LP
 c/o Harvest Management LLC
 John Christ
 600 Madison Avenue; 11th Floor
 New York, NY 10022
 Phone: 212-634-3600
 Fax: 212-634-3636
 mr@harvestmgmt.com
 jc@harvestmgmt.com
	  	$	3,608.80	  	5,552	  	2,776	  	$	9,079.20	  	13,968	  	6,984
							
	 Lewis Opportunity Fund LP
 Lewis Opportunity Fund LP
 Austin Lewis
 45 Rockefeller Plaza
 New York, NY 10011
 Phone: 212-541-4367
 austin@lewisfunds.com
	  	$	13,867.75	  	21,335	  	10,667	  	$	34,882.25	  	53,665	  	26,833
							
	 Meadowbrook Opportunity Fund, LLC
 c/o Meadowbrook Capital Management LLC
 Dan Elekman
 520 Lake Cook Road
 Suite 690
 Deerfield, IL 60015
 Phone: 847-876-1220
 delekman@meadowbrookcapital.com
	  	$	55,471.65	  	85,341	  	42,670	  	$	139,528.35	  	214,659	  	107,330
							
	 Micro Cap Partners, L.P.
 c/o Palo Alto Investors
 William Edwards
 470 University Avenue
 Palo Alto, CA 94301
 Phone: 650-325-0772
	  	$	312,918.45	  	481,413	  	240,706	  	$	787,080.45	  	1,210,893	  	605,447
							
	 Palo Alto Healthcare Fund, L.P.
 c/o Palo Alto Investors
 William Edwards
 470 University Avenue
 Palo Alto, CA 94301
 Phone: 650-325-0772
	  	$	113,788.35	  	175,059	  	87,529	  	$	286,211.25	  	440,325	  	220,163

															
	 Stroller Tod White and Linda
 White, Trustees
of the Tod &
 Linda White Revocable Trust,
 dated 5/21/98
 c/o Princeton Capital Management, Inc.
 Jim Fitzpatrick
 47 Hulfish Street
 Suite 500
 Princeton, NJ 08542
 Phone: 609-924-6867
 info@pcminvest.com
	  	$	56,893.85	  	87,529	  	43,764	  	$	143,105.95	  	220,163	  	110,082
							
	 Branco Weiss
 c/o Princeton Capital Management, Inc.
 Jim Fitzpatrick
 47 Hulfish Street
 Suite 500
 Princeton, NJ 08542
 Phone: 609-924-6867
 info@pcminvest.com
	  	$	142,235.60	  	218,824	  	109,412	  	$	357,763.90	  	550,406	  	275,203
							
	 William H. Reaves – PCM
 c/o Princeton Capital Management, Inc.
 Jim Fitzpatrick
 47 Hulfish Street
 Suite 500
 Princeton, NJ 08542
 Phone: 609-924-6867
 info@pcminvest.com
	  	$	71,117.15	  	109,411	  	54,705	  	$	178,881.95	  	275,203	  	137,602
							
	 Young Enterprise Securities, LLC
 c/o Princeton Capital Management, Inc.
 Jim Fitzpatrick
 47 Hulfish Street
 Suite 500
 Princeton, NJ 08542
 Phone: 609-924-6867
 info@pcminvest.com
	  	$	56,893.85	  	87,529	  	43,764	  	$	143,105.95	  	220,163	  	110,082

															
	 Hugh and Constance Fitzpatrick
 c/o Princeton Capital Management, Inc.
 Jim Fitzpatrick
 47 Hulfish Street
 Suite 500
 Princeton, NJ 08542
 Phone: 609-924-6867
 info@pcminvest.com
	  	$	17,067.70	  	26,258	  	13,129	  	$	42,931.20	  	66,048	  	33,024
							
	 Nancye Allen Fitzpatrick
 c/o Princeton Capital Management, Inc.
 Jim Fitzpatrick
 47 Hulfish Street
 Suite 500
 Princeton, NJ 08542
 Phone: 609-924-6867
 info@pcminvest.com
	  	$	11,378.25	  	17,505	  	8,752	  	$	28,621.45	  	44,033	  	22,017
							
	 ProMed Partners, L.P.
 c/o ProMed Management, Inc.
 Barry Kurokawa
 237 Park Avenue
 9th Floor
 New York, NY 10017
 Phone: 212-692-3626
 bkurokawa@promedmgmt.com
	  	$	88,545.60	  	136,224	  	68,112	  	$	222,719.90	  	342,646	  	171,323
							
	 ProMed Partners II, L.P.
 c/o ProMed Management, Inc.
 Barry Kurokawa
 237 Park Avenue
 9th Floor
 New York, NY 10017
 Phone: 212-692-3626
 bkurokawa@promedmgmt.com
	  	$	22,935.25	  	35,285	  	17,642	  	$	57,690.75	  	88,755	  	44,378

															
	 ProMed Offshore Fund, Ltd.
 c/o ProMed Management, Inc.
 Barry Kurokawa
 237 Park Avenue
 9th Floor
 New York, NY 10017
 Phone: 212-692-3626
 bkurokawa@promedmgmt.com
	  	$	14,396.20	  	22,148	  	11,074	  	$	36,212.80	  	55,712	  	27,856
							
	 ProMed Offshore Fund II, Ltd.
 c/o ProMed Management, Inc.
 Barry Kurokawa
 237 Park Avenue
 9th Floor
 New York, NY 10017
 Phone: 212-692-3626
 bkurokawa@promedmgmt.com
	  	$	300,829.75	  	462,815	  	231,407	  	$	756,674.75	  	1,164,115	  	582,058
							
	 SF Capital Partners Ltd.
 SF Capital Partners Ltd.
 c/o Stark Offshore Management, LLC
 3600 South Lake Drive
 St. Francis, WI 53235
 Attn: Brian Davidson
 Phone: 414-294-7000
 Fax: 414-294-7700
 bdavidson@sf-capital.com
	  	$	853,414.90	  	1,312,946	  	656,473	  	$	2,146,586.00	  	3,302,440	  	1,651,220
							
	 Walker Smith Capital, L.P.
 Walker Smith Capital, L.P.
 Joe Worsham
 300 Crescent Court, Suite 1111
 Dallas, TX 75201
 Phone: 214-756-6073
 joe@walksmith.com
	  	$	12,487.80	  	19,212	  	9,606	  	$	31,411.90	  	48,326	  	24,163

															
	 Walker Smith Capital (QP), L.P.
 Walker Smith Capital (QP), L.P.
 Joe Worsham
 300 Crescent Court, Suite 1111
 Dallas, TX 75201
 Phone: 214-756-6073
 joe@walksmith.com
	  	$	65,712.40	  	101,096	  	50,548	  	$	165,287.20	  	254,288	  	127,144
							
	 Walker Smith International Fund, Ltd.
 Walker Smith International Fund, Ltd.
 Joe Worsham
 300 Crescent Court, Suite 1111
 Dallas, TX 75201
 Phone: 214-756-6073
 joe@walksmith.com
	  	$	92,481.35	  	142,279	  	71,139	  	$	232,618.75	  	357,875	  	178,938
							
	 SRB Greenway Capital, L.P.
 SRB Greenway Capital, L.P.
 Joe Worsham
 300 Crescent Court, Suite 1111
 Dallas, TX 75201
 Phone: 214-756-6073
 joe@walksmith.com
	  	$	26,057.20	  	40,088	  	20,044	  	$	65,543.40	  	100,836	  	50,418
							
	 SRB Greenway Capital (QP), L.P.
 SRB Greenway Capital (QP), L.P.
 Joe Worsham
 300 Crescent Court, Suite 1111
 Dallas, TX 75201
 Phone: 214-756-6073
 joe@walksmith.com
	  	$	16,612.70	  	25,558	  	12,779	  	$	41,787.20	  	64,288	  	32,144
							
	 SRB Greenway Offshore
 Operating Fund,
L.P.
 SRB Greenway Offshore Operating
 Fund, L.P.
 Joe Worsham
 300 Crescent Court, Suite 1111
 Dallas, TX 75201
 Phone: 214-756-6073
 joe@walksmith.com
	  	$	184,906.15	  	284,471	  	142,235	  	$	465,093.85	  	715,529	  	357,765
	 	  	
	
	  	
	  	
	  	
	
	  	
	  	

	 Total
	  	$	3,225,699.10	  	4,962,614	  	2,481,298	  	$	8,113,601.60	  	12,482,464	  	6,241,241
	 	  	
	
	  	
	  	
	  	
	
	  	
	  	

  
  

 Schedule II 
  
 Escrow Agent Wire Instructions 
  
 Mellon Bank 
  
 ABA 043000261 
  
 Reorg Cash 
  
 Curon Medical 
  
 Acct # 1002331 
  
 Attn Evelyn O’Connor 

 Exhibit A 
  

Form of Warrant 

 Exhibit B 
  

Escrow Agreement 

 

 
  
 ESCROW AGENT AGREEMENT

 ESCROW AGREEMENT 
  
 ESCROW AGREEMENT (the “Escrow Agreement”), dated as of April 7, 2005, among Curon Medical, Inc., a Delaware
corporation (“Company”), the investors on Schedule A attached hereto (each, an “Investor,” together, the “Investors”), Atlas Equity I, Ltd. (the “Investor Representative”), and MELLON INVESTOR SERVICES LLC, a
New Jersey limited liability company (the “Escrow Agent”). 
  
 WHEREAS, the Company and the Investors have entered into a Stock Purchase Agreement in connection with a private placement undertaken by the Company (the “Stock Purchase Agreement”); and 
  
 WHEREAS, the Company and the Investors have agreed to deposit immediately
available funds for a First Closing and a Second Closing (as defined in the Stock Purchase Agreement) (the “Funds”) to the Escrow Agent for deposit into an escrow account (the “Escrow Account”) to be established in accordance
with this Escrow Agreement; and 
  
 WHEREAS, the Company and the
Investors desire to appoint Mellon Investor Services LLC to act as Escrow Agent for the Funds and any other funds deposited or held in the Escrow Account from time to time in accordance with this Escrow Agreement, including without limitation
interest, income or earnings thereon (collectively the “Escrowed Property”). 
  
 NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties hereto agree as follows: 
  
 Section 1. Appointment of the Escrow Agent and Investor Representative. 
  
 The Escrow Agent is hereby appointed, and hereby agrees, to act as the
Escrow Agent hereunder upon the terms set forth herein, and to accept the Funds, deposit the Funds in the Escrow Account and otherwise perform the duties of the Escrow Agent expressly set forth in this Escrow Agreement. The Escrow Agent shall hold
and safeguard the Funds and any other Escrowed Property deposited or held from time to time in the Escrow Account during the term of this Escrow Agreement. The Investor Representative is hereby appointed, and hereby agrees, to act as
attorney-in-fact on behalf of all of the Investors with regards to the subject matter of this Escrow Agreement. 
  
 Section 2. Receipt of Property. 
  
 (a) The Escrow Agent hereby acknowledges receipt from the Investors of immediately available funds in the aggregate amount of $11,339,300.70. 

 
 (b) So long as the Escrow Agent is holding the Funds or any other funds or
cash in the Escrow Account in accordance with this Agreement, it shall invest such Funds in, and pay interest at the Dreyfus General Money Market Fund Class B rate. All income and earnings from the investment of the Escrowed Property shall be
credited to, and become a part of, the Escrowed Property, and any losses on any such investments shall be debited to the Escrow 

 
Account. The Escrow Agent shall have no duty, responsibility or obligation to invest any funds or cash held in the Escrow Account other than in accordance
with this Section 2(b). The Escrow Agent shall have no liability or responsibility for any investment losses, including without limitation any market loss on any investment liquidated (whether at or prior to maturity) in order to make a payment
required under this Escrow Agreement. The Escrow Agent may, in making or disposing of any investment permitted by this Escrow Agreement, deal with itself, in its individual capacity, or any of its affiliates, whether or not it or such affiliate is
acting as a subagent of the Escrow Agent or for any third person or dealing as principal for its own account. 
  
 Section 3. Disbursements from Escrow Account. 
  
 (a) At any time on or before June 30, 2005 (the “Escrow Termination Date”), the Escrow Agent shall make disbursements from the Escrow Account
upon receipt of joint written instructions executed by the Investor Representative and an Appropriate Officer of the Company instructing the Escrow Agent how to disburse the Escrowed Property or any part thereof (including without limitation income
or earnings thereon), and specifically setting forth the exact amount of cash to be disbursed and the identity of the person or entity to which a disbursement is to be made, then the Escrow Agent shall forthwith transfer from the Escrow Account and
disburse the Escrowed Property or such part thereof in accordance with such instructions. 
  
 (b) Without affecting any of the rights and obligations of Escrow Agent or limiting the provisions of section 3(a) hereof, and for the sole purpose of setting forth the rights and obligations of the Investors, the
Investor Representative, and the Company with regards to the release of the Escrowed Property, the Investors, the Investor Representative, and the Company agree that: 
  
 (i) In the event the conditions to the First Closing are fulfilled, by satisfaction or waiver, by both the
Company and the Investors prior to the Escrow Termination Date, pursuant to Section 3(a) hereof, the Investor Representative shall execute joint written instructions with an Appropriate Officer of the Company to direct Escrow Agent to promptly
disburse all Funds attributable to the First Closing to the Company; 
  
 (ii) In the event the conditions to the Second Closing are satisfied prior to the Escrow Termination Date, the Investor Representative shall execute joint written instructions with an Appropriate Officer of the
Company to direct Escrow Agent to promptly disburse the Funds to the Company, and any remaining Escrowed Property shall be returned to the Investors; 
  
 (iii) In the event the conditions to the Second Closing are not satisfied prior to the Escrow Termination Date, the Company shall cause an
Appropriate Officer of the Company to execute joint written instructions with the Investor Representative to direct Escrow Agent to promptly disburse the Escrowed Property to the Investors in accordance with their pro rata interest therein; and

  

 - 2 - 

 (iv) Notwithstanding the foregoing, in the event the Company has not received stockholder
approval of the transactions contemplated by the Stock Purchase Agreement within 75 days of the date hereof, the Company shall cause an Appropriate Officer of the Company to execute joint written instructions with the Investor Representative to
direct Escrow Agent to promptly disburse that portion of the Escrowed Property to an Investor who elects to have its pro rata portion of the Escrowed Property released from escrow. 
  
 (c) The Escrow Agent shall disburse the Escrowed Property only in accordance with this Section 3 or Section 5. 

 
 (d) For purposes of this Escrow Agreement, the term “Appropriate
Officers” means the President, Chief Executive Officer, or Chief Financial Officer of the Company as set forth on the Company’s most recently filed report with the Securities and Exchange Commission. 
  
 (e) The transfer of any of the Escrowed Property by the Escrow Agent to any
party pursuant to this Section 3 shall be made by such means as shall be set forth in the joint instructions from the Company and the Investors delivered and satisfactory to the Escrow Agent. 
  
 Section 4. The Escrow Agent. 
  
 The Escrow Agent: 
  
 (i) shall act hereunder as an escrow agent only and shall
not be responsible or liable in any matter whatever for the sufficiency, collection, correctness, genuineness or validity of any revenues, cash, payments, securities, property, funds, investments, income, earnings or other amounts deposited with or
held by it or for the identity, authority or rights of any person or entity executing and delivering or purporting to execute or deliver any thereof to the Escrow Agent; 
  
 (ii) shall be fully protected in acting upon any written notice, instruction, direction, request or other
communication, paper or document which the Escrow Agent believes to be genuine, and shall have no duty to inquire into or investigate the validity, accuracy or content of any thereof; 
  
 (iii) shall not be liable for any error of judgment or for any action taken, suffered or omitted to be taken
except in the case of its own gross negligence or bad faith, as determined by a final non-appealable order, judgment, decree or ruling of a court of competent jurisdiction. In no event shall the Escrow Agent be (A) liable for acting in accordance
with a notice, instruction, direction, request or other communication, paper or document from the Company or the Investor Representative or (B) liable or responsible for special, punitive, indirect, consequential or incidental loss or damages of any
kind whatsoever to any person or entity (including without limitation lost profits), even if the Escrow Agent has been advised of the likelihood of such loss or damage. Any liability of the 

  

 - 3 - 

 
Escrow Agent under this Escrow Agreement will be limited to the amount of fees paid to the Escrow Agent; 
  
 (iv) may consult with and obtain advice from counsel (who
may be counsel to a party hereto or an employee of the Escrow Agent) and shall be fully protected in taking, suffering or omitting to take any action in reliance on said advice; 
  
 (v) shall have no duties, responsibilities or obligations as the Escrow Agent except those which are
expressly set forth herein, and in any modification or amendment hereof to which the Escrow Agent has consented in writing, and no duties, responsibilities or obligations shall be implied or inferred. Without limiting the foregoing, the Escrow Agent
shall not be subject to, nor be required to comply with, or determine if any person or entity has complied with, the Stock Purchase Agreement or any other agreement between or among the parties hereto, even though reference thereto may be made in
this Escrow Agreement, or to comply with any notice, instruction, direction, request or other communication, paper or document other than as expressly set forth in this Escrow Agreement; 
  
 (vi) may execute or perform any duty, responsibility or obligation hereunder either directly or through
agents, attorneys, accountants or other experts; 
  
 (vii) may engage or be interested in any financial or other transaction with the Company or any party hereto or affiliate thereof, and may act on, or as depositary, trustee or agent for, any committee or body of holders of obligations of
such party or affiliate, as freely as if it were not the Escrow Agent hereunder; 
  
 (viii) shall not be obligated to expend or risk its own funds or to take any action which it believes would expose it to expense or
liability or to a risk of incurring expense or liability, unless it has been furnished with assurances of repayment or indemnity satisfactory to it; 
  
 (ix) shall not take instructions or directions except those given in accordance with this Escrow Agreement; 
  
 (x) shall not incur any liability for not performing any
act, duty, obligation or responsibility by reason of any occurrence beyond the control of the Escrow Agent (including without limitation any act or provision of any present or future law or regulation or governmental authority, any act of God, war,
civil disorder or failure of any means of communication); and 
  
 (xi) shall not be called upon to advise any person or entity as to any investments with respect to any security, property or funds held in escrow hereunder or the dividends, distributions, income, interest or earnings
thereon. 
  

 - 4 - 

 Section 5. Miscellaneous. 
  
 (a) Fees and Expenses. The Escrow Agent shall be entitled to reasonable compensation for its services as Escrow Agent
hereunder in accordance with the Schedule of Fees attached hereto. The Company shall pay all amounts due hereunder upon invoice from the Escrow Agent after the Escrow Termination Date. The obligations contained in this Section 5(a) shall survive the
termination of this Escrow Agreement and the resignation or removal of the Escrow Agreement. 
  
 (b) Indemnification. The Company and each Investor (to the extent of its interest in the Escrowed Property), jointly and severally, agree to indemnify, defend, protect, save and keep harmless the Escrow Agent
and its affiliates and their respective successors, assigns, directors, officers, managers, employees, agents, attorneys, accountants and experts (collectively the “Indemnitees”), from and against any and all direct losses, damages,
claims, liabilities, penalties, judgments, settlements, actions, suits, proceedings, litigation, investigations, and costs or expenses therefrom, including without limitation reasonable fees and disbursements of counsel (collectively
“Losses”), that may be imposed on, incurred by, or asserted against any Indemnitee, at any time, and in any way relating to or arising out of the execution, delivery or performance of this Escrow Agreement, the enforcement of any rights or
remedies under or in connection with this Escrow Agreement, the establishment of the Escrow Account, the acceptance or administration of the Escrowed Property and any payment, transfer or other application of funds pursuant to this Escrow Agreement,
or as may arise by reason of any act, omission or error of the Indemnitee; provided, however, that no Indemnitee shall be entitled to be so indemnified, defended, protected, saved and kept harmless to the extent such Loss was
proximately caused by its own gross negligence or bad faith, as determined by a final, non-appealable order, judgment, decree or ruling of a court of competent jurisdiction. The obligations contained in this Section 5(b) shall survive the
termination of this Escrow Agreement and the resignation or removal of the Escrow Agreement. 
  
 (c) Termination. Except as specifically set forth in Sections 5(a), 5(b) and 5(n) hereof, this Escrow Agreement shall terminate upon final distribution and disbursement of all of the Escrowed Property,
including income and earnings thereon, in accordance with Section 3 hereof. 
  
 (d) Notices. All notices, instructions, directions, requests or other communications hereunder shall be in writing and shall be delivered personally, sent by facsimile transmission (with immediate confirmation
of receipt thereafter by telephone or otherwise), or sent by U.S. registered, certified or express mail, first class postage prepaid, return receipt requested, or sent by a nationally recognized overnight courier service, marked for overnight
delivery. Any such notice, instruction, direction, request or communication shall be deemed given when so delivered personally, or sent by facsimile transmission (provided confirmation of receipt is received immediately thereafter); or if sent by
express mail or overnight courier, one (1) Business Day after the date of delivery to a U.S. Post Office or the courier service marked for overnight delivery; or if so sent by registered or certified mail, seven (7) days after the date of deposit in
the mails; in each case addressed to each party at its address set forth beneath its signature hereto or to such other address as a party hereto may specify from time to time by notice to each other party given as provided herein. For purposes of
this Escrow 

  

 - 5 - 

 
Agreement, the term “Business Day” means any day other than a Saturday, Sunday or a day on which commercial banks in the States of New Jersey or
New York are required or authorized by law to close. 
  
 (e)
Benefit of Agreement. This Escrow Agreement and all rights and obligations hereunder in and to the Escrowed Property and the Escrow Account and any and all written instruments evidencing investments made from the funds held in the Escrow
Account shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. 
  
 (f) Amendment, Modification, Waiver and Consent. No amendment, modification or waiver of any provision of this Escrow Agreement, nor any consent to
any departure therefrom, by any party hereto shall be valid or effective for any purpose unless the same shall be in writing and signed by the party to be charged therewith, and then such amendment, modification, waiver or consent shall be effective
only in the specific instance and for the specific purpose given. Any notice to, or demand on, any party for any purpose not specifically required of another hereunder shall not entitle the first party to any other or further notice or demand in the
same, similar or other circumstances unless specifically required hereunder. 
  
 (g) Conflicts and Severability. In the event of any conflict between the terms and provisions of this Escrow Agreement and those of the Stock Purchase Agreement, the terms and conditions of this Escrow
Agreement shall control. If any provision of this Escrow Agreement is determined to be prohibited or unenforceable by reason of any applicable law of a jurisdiction, then such provision shall, as to such jurisdiction, be ineffective to the extent of
such prohibition or unenforceability without invalidating the remaining provisions thereof, and any such prohibition or unenforceability in such jurisdiction shall not invalidate or render unenforceable such provisions in any other jurisdiction.
Where, however, the conflicting provisions of any such applicable law may be waived, they are hereby irrevocably waived by the parties hereto to the fullest extent permitted by law, to the end that this Escrow Agreement shall be enforced as written.

  
 (h) No Interest of Third Parties. Except as expressly
provided in Section 5(b), nothing in this Escrow Agreement, whether express or implied, shall be construed to give to any person or entity other than the parties hereto any legal or equitable right, remedy, interest or claim under or in respect of
this Escrow Agreement or any funds escrowed hereunder. 
  
 (i)
Titles and Headings. Titles and headings to sections herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Escrow Agreement. 
  
 (j) Applicable Law and Forum. This Escrow Agreement and all
amendments, modifications and waivers thereof shall, in all respects, be governed by and construed and enforced in accordance with the internal laws (without regard to principles of conflicts of law) of the State of New York. Each party hereto
hereby irrevocably submits to the personal jurisdiction of the state and federal courts located within the City and State of New York with respect to any action, suit or proceeding relating to or arising from this Escrow Agreement. Each party hereto

  

 - 6 - 

 
irrevocably waives (i) any claim or defense based upon improper venue or inconvenient forum with respect to any action, suit or proceeding brought in any
such court and (ii) the right to trial by jury in any action, suit or proceeding relating to or arising under this Escrow Agreement. Each party waives personal service of process and consents to the service of process by the manner set forth in
Section 5(d), in addition to any other method of service of process permitted by applicable law. 
  
 (k) Execution in Counterparts. This Escrow Agreement may be executed in one or more counterparts, each of which shall be an original and all of
which, taken together, shall be considered one and the same agreement, and shall become a binding agreement when one or more counterparts have been signed by each party hereto and delivered to each other party or such party’s representative.

  
 (l) Resignation or Replacement of Escrow Agent.

  
 (i) The Escrow Agent may at any time resign
by giving not less than 30 days’ notice to the Company and the Investor Representative, or may be removed jointly by the Company and the Investor Representative by giving not less than 30 days’ notice to the Escrow Agent. 
  
 (ii) Any person or entity into which the Escrow Agent may be
merged or converted or with which it may be consolidated, or any person or entity resulting from any merger, conversion or consolidation to which the Escrow Agent shall be a party, or any person or entity to which substantially all the stock
transfer business of the Escrow Agent may be transferred, shall automatically be the Escrow Agent under this Escrow Agreement without further act. 
  
 (m) Ambiguity and Disputes. 
  
 (i) In the event the Escrow Agent believes any ambiguity or uncertainty exists hereunder or in any notice, instruction, direction, request
or other communication, paper or document received by the Escrow Agent hereunder, Escrow Agent, may, in its sole discretion, refrain from taking any action, and shall be fully protected and shall not be liable in any way to the Company, the Investor
Representative, or any Investor, or other person or entity for refraining from taking such action, unless the Escrow Agent receives written instructions signed by the Company and the Investor Representative which eliminates such ambiguity or
uncertainty to the satisfaction of Escrow Agent. 
  
 (ii) If any dispute between or conflicting claims by or among the Company, the Investor Representative, or any Investor, or other person or entity with respect to this Escrow Agreement, the Escrowed Property or the Escrow Account arises,
the Escrow Agent may, in its sole discretion, at its option (A) initiate an action in interpleader or another appropriate 

  

 - 7 - 

 
action, suit or proceeding in a court of competent jurisdiction seeking to resolve such dispute or claims and/or (B) refrain from complying with any claim,
notice, instruction, direction, request or other communication, paper or document, so long as such dispute or conflict shall continue, and (in either case) shall be fully protected and shall not be liable in any way to the Company, the Investor
Representatives, any Investor, or other person or entity for failure or refusal to comply with such conflicting claims, notices, instructions, directions, requests, communications, papers or documents until the Escrow Agent is satisfied, in its sole
discretion, that such conflicting claims, notices, instructions, directions, requests, communications, papers or documents have been definitively determined by a final, non-appealable order, judgment, decree or ruling of a court of competent
jurisdiction or settled by agreement between the conflicting parties as evidenced in a writing satisfactory to the Escrow Agent. 
  
 (n) Tax Issues. The parties acknowledge that the Escrow Agent does not have any interest in the Escrowed Property or the Escrow Account, but is
serving only as escrow holder hereunder. Without limiting the foregoing, the Investors shall be responsible for any taxes relating to the Escrowed Property, the Escrow Account and funds on deposit therein and the income and earnings thereon. Any
disbursements of the Escrowed Property or payments from the Escrow Account shall be subject to withholding taxes and regulations then in force under the United States Federal Income Tax Code. For tax purposes, the Escrow Agent shall report all
income and earnings from the investment of the Escrowed Property to the extent such income or earnings are distributed by the Escrow Agent to any person or entity pursuant to this Escrow Agreement, as being allocated to such person or entity and.
The Investors will provide the Escrow Agent with appropriate forms for tax certifications, as requested by the Escrow Agent. This Section 5(n) shall survive the termination of this Escrow Agreement and the resignation or removal of the Escrow Agent.

  
 (o) Compliance With Process. Notwithstanding anything
in this Escrow Agreement to the contrary, if at any time the Escrow Agent is served with any judicial or administrative order, judgment, decree, writ or other form of judicial or administrative process which in any way affects the Escrow Agent, the
Escrow Account or the Escrowed Property (including without limitation orders of attachment or garnishment or levies or injunctions), the Escrow Agent is authorized to comply therewith in any manner it deems appropriate, and shall be fully protected
from doing so even if such order, judgement, decree, writ or process may be subsequently amended, modified, vacated or otherwise determined to be invalid or without legal force or effect. 
  
 (p) Representations. The Company and each Investor represents and warrants, as to itself, that it is a corporation
duly organized, validly existing in good standing under its respective jurisdiction of organization. The Company and each Investor represents and warrants, as to itself, that it has all requisite power and authority to execute, deliver and perform
its obligations under this Escrow Agreement and this Escrow Agreement has been duly authorized, executed and delivered by it and constitutes its legal, valid, binding and enforceable obligations and the execution, delivery and performance by it of
this Escrow Agreement do not and will not violate or require consent under any of its organizational documents, any law, 

  

 - 8 - 

 
statute, rule, regulation or ordinance or contract, agreement, instrument, indenture or other undertaking to which it is a party or by which it or its
property may be bound. Investor Representative further represents and warrants that he has the irrevocable right, power and authority to act on behalf of and bind all of the Investors, to give and receive notices, instructions, directions, requests
or other communications hereunder and to make determinations that may be necessary or appropriate under this Escrow Agreement. 
  
 (q) Merger Clause. This Escrow Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof, and supersedes
any prior oral or written agreements in regard thereto. 
  
 (r)
Cumulative Remedies. The rights and remedies of the Escrow Agent set forth in this Escrow Agreement shall be cumulative, and not exclusive, of any rights and remedies available to it at law or equity or otherwise. 
  
 [Remainder of Page Intentionally Left Blank] 
  

 - 9 - 

 IN WITNESS WHEREOF, the parties have executed this Escrow Agreement as of the day and year first
above written. 
  

			
	CURON MEDICAL, INC.
		
	By:	 	  

	Name:	 	 
	Title:	 	 
		
	 	 	Taxpayer Identification Number:
		
	 	 	Address for Notices:
	
	 ATLAS EQUITY I., LTD.
 in its capacity as the
Investor Representative

		
	By:	 	  

	Name:	 	 
	Title:	 	 
		
	 	 	Address for Notices:
	
	 MELLON INVESTOR SERVICES LLC,
 as Escrow
Agent

		
	By:	 	  

	Name:	 	 
	Title:	 	 
		
	 	 	Address for Notices:
	
	 85 Challenger Road

	 Ridgefield Park, NJ 07660

	 Attention: Relationship Manager

			
	 [INVESTOR]

		
	 By:
	 	  

	 Name:
	 	 
	 Title:
	 	 
		
	 	 	 Taxpayer Identification Number:

		
	 	 	 Address for Notices:

  

 Signature Page to Escrow Agreement 

 Schedule A 
  
 Schedule of Investors 

 MELLON INVESTOR SERVICES LLC 
  
 Schedule of Fees 
 As Cash Escrow Agent for 
 Private Placement 
  

				
	 Facility & Set-Up Fee, per Escrow Account
	  	$	5,000.00

  
 Payable at the start
of the Billing Year, includes: 
  

	 	•	 	Dedicated Administrative Team 

  

	 	•	 	File Application on Multiple Systems 

  

	 	•	 	Daily Balancing/Proofing 

  

	 	•	 	Administrative & Operational Consultative Services 

  

	 	•	 	Interest Compilation & Calculation 

  

	 	•	 	Data Entry & System Updates 

  

	 	•	 	Quality Control 

  

	 	•	 	Check & Certificate Preparation Work 

  

	 	•	 	Standard 1099 Issuance & Tax Reporting, if necessary 

  

	 	•	 	Legal Items & Correspondence 

  
 Payments 
  

				
	 •      Checks per Distribution
	  	$	20.00/Check
	 •      Wires per Distribution
	  	$	125.00/Wire

  
  

			
	 Out of Pocket Expenses
	  	Additional

  
 Including Postage,
Printing, Stationery, 
 Overtime, Transportation, Microfilming, etc. 
  

	 	•	 	This proposal is based on the following terms: 

  

	 	•	 	Possibly 7 to 15 investors 

  

	 	•	 	Escrow Period of approximately 3 months 

  

	 	•	 	Total Amount of Escrow Proceeds being approximately $10 million 

 Exhibit C 
  

Form of Legal Opinion (Second Closing) 
  
             , 2005 
  
 To the Persons and Entities Listed on Schedule I to the 
 Curon Medical, Inc. Stock Purchase Agreement 
 Dated as of             , 2005

  
 Re:    Curon Medical, Inc.

  
 Ladies and Gentlemen: 
  
 Reference is made to the Stock Purchase Agreement dated as of
            , 2005 (the “Agreement”), by and among Curon Medical, Inc., a Delaware corporation (the “Company”), and the persons and entities listed
in Schedule I to the Agreement (the “Investors”), which provides for the issuance by the Company to the Investors of              shares of Common Stock of
the Company in a second closing (the “Second Closing Shares”) and warrants (the “Second Closing Warrants”) initially exercisable for             
shares of Common Stock of the Company in a second closing (the “Second Closing Warrant Shares”). The Second Closing Shares, the Second Closing Warrants, and the Second Closing Warrant Shares are referred to herein collectively as
the “Securities.” This opinion is rendered to the Investors pursuant to Section          of the Agreement, and all terms used herein have the meanings defined for them in the
Agreement unless otherwise defined herein. Reference in this opinion to the Agreement excludes any schedule or substantive agreement attached as an exhibit to the Agreement, unless otherwise indicated herein. The Agreement and the forms of the
Second Closing Warrants are sometimes referred to collectively herein as the “Operative Documents.” Capitalized terms used herein have the same meanings given to them in the Agreement, unless otherwise defined herein. 
  
 We have acted as counsel for the Company in connection with the negotiation of the Agreement
and the issuance of the Securities. As such counsel, we have made such legal and factual examinations and inquiries, as we have deemed advisable or necessary for the purpose of rendering this opinion. In addition, we have examined originals or
copies of such corporate records of the Company, certificates of public officials and such other documents that we consider necessary or advisable for the purpose of rendering this opinion 
  
 In such examination, we have assumed the following: (a) the genuineness of all signatures;
(b) the authenticity of all documents submitted to us as originals; (c) the conformity to authentic original documents of all documents submitted to us as copies; (d) the truth, accuracy and completeness of the information, factual matters,
representations and warranties contained in the records, documents, instruments and certificates we have reviewed as of their stated dates and as of the date hereof; (e) the legal capacity of natural persons; (f) except as specifically covered in
the opinions set forth below, the due authorization, execution and delivery on behalf of the respective parties thereto of documents 

 
referred to herein and the legal, valid and binding effect thereof on such parties; and (g) the absence of any evidence extrinsic to the provisions of the
written agreements between the parties that the parties intended a meaning contrary to that expressed by those provisions. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied
upon oral or written statements and representations of officers and other representatives of the Company and you. 
  
 As used in this opinion, the expression “to our knowledge,” “known to us” or similar language with reference to matters of fact refers to the current
actual knowledge of the attorneys of this firm who have worked on matters for the Company in connection with the Agreement and the transactions contemplated thereby. Except to the extent expressly set forth herein or as we otherwise believe to be
necessary to our opinion, we have not undertaken any independent investigation to determine the existence or absence of any fact, and no inference as to our knowledge of the existence or absence of any fact should be drawn from our representation of
the Company or the rendering of the opinion set forth below. 
  
 For purposes of
this opinion, we are assuming that the Investors have all requisite power and authority, and have taken any and all necessary corporate or partnership action, to execute and deliver the Agreement, and we are assuming that the representations and
warranties made by the Investors in the Agreement and pursuant thereto are true and correct. We are also assuming that the Investors have purchased the Securities for value, in good faith and without notice of any adverse claims within the meaning
of the Delaware General Corporation Law. We have also assumed that no offers or sales of the Securities have been made other than to “accredited investors” within the meaning of Rule 501 of the Securities Act of 1933, as amended (the
“Securities Act”). Moreover, we have assumed that the offers and sales of the Securities have been conducted in the manner contemplated by the Agreement and, in this regard, we have relied upon the applicable representations, warranties,
covenants and agreements contained in the Agreement and assumed compliance by the respective parties therewith. 
  
 We are members of the Bar of the State of California and we express no opinion as to any matter relating to the laws of any jurisdiction other than the federal laws of
the United States of America, the General Corporation Law of the State of Delaware and the laws of the State of California. 
  
 In rendering the opinion in paragraph 1 below, we note that we have relied solely on certificates as of a recent date of the Secretary of State of Delaware and of the
Secretary of State of California as to the good standing of the Company as a corporation incorporated under the laws of the State of Delaware and the State of California. In rendering the opinion in paragraph 6 below, we note that we have not
conducted a docket search in any jurisdiction with respect to litigation that may be pending against the Company or any of its officers or directors. 
  
 The opinions hereinafter expressed are subject to the following additional qualifications: 
  
 (i) We express no opinion as to the effect of applicable bankruptcy, insolvency, reorganization, moratorium or other similar
federal or state laws affecting the rights of creditors; 
  
 (ii)
We express no opinion as to the effect or availability of rules of law governing specific performance, injunctive relief or other equitable remedies (regardless of whether any such remedy is considered in a proceeding at law or in equity);

 (iii) We express no opinion with respect to the validity, binding nature or enforceability of any
provisions of any Operative Documents imposing penalties or forfeitures, late payment charges upon delinquency in payment or the occurrence of a default to the extent they constitute a penalty or forfeiture or are otherwise contrary to public
policy; 
  
 (iv) We express no opinion as to any provision of the
Operative Documents requiring written amendments or waivers of such documents insofar as it suggests that oral or other modifications, amendments or waivers could not be effectively agreed upon by the parties or that the doctrine of promissory
estoppel might not apply; 
  
 (v) This opinion is qualified by the
limitations imposed by statutes and principles of law and equity that provide that certain covenants and provisions of agreements are unenforceable where such covenants or provisions are unconscionable or contrary to public policy or where
enforcement of such covenants or provisions under the circumstances would violate the enforcing party’s implied covenant of good faith and fair dealing; 
  
 (vi) We express no opinion as to compliance with the anti-fraud provisions of applicable securities laws; and 
  
 (vii) We express no opinion as to the enforceability of the indemnification
and contribution provisions of the Agreement to the extent the provisions thereof may be subject to limitations of public policy and the effect of applicable statutes and judicial decisions. 
  
 Based upon and subject to the foregoing, and except as set forth in the SEC
Documents, we are of the opinion that: 
  
 1. The Company is a corporation duly
incorporated and validly existing under, and by virtue of, the laws of the State of Delaware and is in good standing under such laws. The Company has requisite corporate power to own and operate its properties and assets, and to carry on its
business as presently conducted. The Company is qualified to do business as a foreign corporation in the State of California. 
  
 2. The Company has all requisite legal and corporate power to sell and issue the Securities under the Agreement. 
  
 3. The Second Closing Shares have been duly authorized and when issued, delivered and paid
for in accordance with the terms of the Agreement, will be validly issued, fully paid and nonassessable and free of any pre-emptive or similar rights. The Second Closing Warrants have been duly authorized and when issued, delivered and paid for in
accordance with the terms of the Agreement, will be validly issued, fully paid and nonassessable and free of any pre-emptive or similar rights. The Second Closing Warrant Shares to be issued upon exercise of the Second Closing Warrants have been
duly authorized and reserved for issuance and, when such Second Closing Warrants have been exercised, issued and delivered against payment therefor in accordance with their terms, will be validly issued, fully paid and nonassessable and free of any
pre-emptive or similar rights. 
  
 4. All corporate action on the part of the
Company, its directors and stockholders necessary for the authorization, sale, issuance and delivery of the Second Closing Shares and the Second Closing Warrants has been taken. 

 5. The issuance of the Second Closing Shares and the Second Closing Warrants do not violate any provision of the
Certificate of Incorporation or Bylaws, or any provision of any applicable federal or state law, rule or regulation known to us to be customarily applicable to transactions of this nature. The issuance of the Second Closing Shares and the Second
Closing Warrants do not violate, or constitute a default under, any contract or agreement or instrument filed as an exhibit to the Company’s filings with the Securities and Exchange Commission pursuant to Item 601(b)(10) of Regulation S-K to
which the Company is a party or by which the Company is bound. 
  
 6. Except as
identified in the Agreement, and as disclosed in filings with the Securities and Exchange Commission, to our knowledge there are no actions, suits, proceedings or investigations pending against the Company or its properties before any court or
governmental agency nor, to our knowledge, has the Company received any written threat thereof. 
  
 7. No consent, approval or authorization of or designation, declaration or filing with any governmental authority on the part of the Company is required in connection with the offer, sale or issuance of the
Securities, except the (i) filing of an amended Form D pursuant to Regulation D under the Securities Act of 1933, as amended (ii) the registration of the Second Closing Shares, and the Second Closing Warrant Shares under the Securities Act of 1933,
as amended, pursuant to the terms of the Agreement and after their initial issuance and sale by the Company; and (iii) the filing of a notification with the Nasdaq Stock Market for the listing of the Second Closing Shares and the Second Closing
Warrant Shares. 
  
 8. Subject to the accuracy of the Investors’
representations in Section 3 of the Agreement, the offer, sale and issuance of the Securities in conformity with the terms of the Agreement constitute transactions exempt from the registration requirements of Section 5 of the Securities Act of 1933,
as amended. 
  
 This opinion is furnished to the Investors solely for their
benefit in connection with the purchase of the Securities, and may not be relied upon by any other person or for any other purpose without our prior written consent. We assume no obligation to inform you of any facts, circumstances, events or
changes in the law that may arise or be brought to our attention after the date of this opinion that may alter, affect or modify the opinions expressed herein.Form of Common Stock Purchase Warrant

 Exhibit 4.2 
  

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO,
OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933. 
  

			
	 Warrant No.
                    
	  	Date of Issuance:                         

  
 CURON MEDICAL, INC.

  
 Common Stock Purchase Warrant 
  
 CURON MEDICAL, INC. (the “Company”), for value received, hereby
certifies that                          or its registered assigns (the “Registered Holder”), is entitled,
subject to the terms set forth below, to purchase [equal to fifty percent (50%) of the equity shares issued to the Registered Holder at the applicable Closing] shares of Common Stock of the Company (the “Warrant Stock”) at an exercise
price per share of $1.00 (the “Exercise Price”). The number of shares of Warrant Stock issuable upon exercise of this Warrant and the Exercise Price shall be adjusted from time to time pursuant to the provisions of this Warrant.
Capitalized terms that are used and not defined in this Warrant that are defined in the Stock Purchase Agreement, dated                 , 2005, to which the
Company and the Registered Holder are parties (the “Purchase Agreement”), shall have the respective definitions set forth in the Purchase Agreement. 
  

1. Exercise. 
  
 (a) Manner of Exercise. 
  
 (i) Cash Exercise. The Registered Holder may deliver immediately available funds; or 
  
 (ii) Cashless Exercise. If an Exercise Notice (in the form attached hereto) is delivered at a time when a
registration statement permitting the Registered Holder to resell the Warrant Stock is not then effective or the prospectus forming a part thereof is not then available to the Registered Holder for the resale of the Warrant Stock, then the
Registered Holder may notify the Company in an Exercise Notice of its election to utilize cashless exercise, in which event the Company shall issue to the Registered Holder the amount of Warrant Stock determined as follows: 
  
 X = Y [(A-B)/A] 
  
 where: 
  
 X = the amount of Warrant Stock to be issued to the Registered Holder. 

 Y = the amount of Warrant Stock with respect to which this Warrant is being exercised. 
  
 A = the average of the closing prices for the five trading days immediately
prior to (but not including) the date of exercise. 
  
 B = the
Exercise Price. 
  
 For purposes of Rule 144 promulgated under the
Act, it is intended, understood and acknowledged that the Warrant Stock issued in a cashless exercise transaction shall be deemed to have been acquired by the Registered Holder, and the holding period for the Warrant Stock shall be deemed to have
commenced, on the date this Warrant was originally issued. 
  
 (b)
Limitations on Exercise. This Warrant shall be exercisable by the Registered Holder at any time and from time to time on or after [6 months and 1 day after the date of the First Closing / the date of the Second Closing] and through and
including [5 years from the date of issuance]. Notwithstanding anything to the contrary contained herein, the amount of Warrant Stock that may be acquired by the Registered Holder upon any exercise of this Warrant (or otherwise in respect hereof)
shall be limited to the extent necessary to insure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by such Registered Holder and its affiliates and any other Persons whose
beneficial ownership of Common Stock would be aggregated with the Registered Holder’s for purposes of Section 13(d) of the 1934 Act, does not exceed 9.999% of the total number of issued and outstanding shares of Common Stock (including for such
purpose the shares of Common Stock issuable upon such exercise). For such purposes, beneficial ownership shall be determined in accordance with Section 13(d) of the 1934 Act and the rules and regulations promulgated thereunder. This provision shall
not restrict the number of shares of Common Stock which a Registered Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Registered Holder may receive in the event of a Fundamental
Transaction as contemplated in Section 3 of this Warrant. This restriction may not be waived. 
  
 (c) Delivery to Registered Holder. 
  
 (i) To effect exercises hereunder, the Registered Holder shall not be required to physically surrender this Warrant unless the aggregate Warrant Stock represented by this Warrant is being exercised. Upon delivery of
the Exercise Notice (in the form attached hereto) to the Company (with the attached Warrant Stock Exercise Log) at its address for notice set forth herein and upon payment of the Exercise Price multiplied by the amount of Warrant Stock that the
Registered Holder intends to purchase hereunder, the Company shall promptly (but in no event later than three trading days after the Date of Exercise (as defined herein)) issue and deliver to the Registered Holder, a certificate for the Warrant
Stock issuable upon such exercise, which, unless there is then an effective registration statement covering distributions of the Warrant Stock, shall bear restrictive legends. The Company shall, upon request of the Registered Holder and subsequent
to the date on which a registration statement covering the resale of the Warrant Stock has been declared effective by the Commission, use its reasonable best efforts to deliver Warrant Stock hereunder electronically through the Depository Trust
Corporation or another established clearing corporation performing similar functions, if available, provided, that, the Company may, but will not 

  

 -2- 

 
be required to change its transfer agent if its current transfer agent cannot deliver Warrant Stock electronically through the Depository Trust Corporation.
A “Date of Exercise” means the date on which the Registered Holder shall have delivered to the Company: (i) the Exercise Notice (with the Warrant Exercise Log attached to it), appropriately completed and duly signed and (ii) if such
Registered Holder is not utilizing the cashless exercise provisions set forth in this Warrant, payment of the Exercise Price for the number of Warrant Stock so indicated by the Registered Holder to be purchased. 
  
 (ii) If by the third trading day after a Date of Exercise the Company fails
to deliver the required number of Warrant Stock in the manner required hereunder, then the Registered Holder will have the right to rescind such exercise. 
  
 (iii) If by the third trading day after a Date of Exercise the Company fails to deliver the required amount of Warrant Stock in the manner required
hereunder, and if after such third trading day and prior to the receipt of such Warrant Stock, the Registered Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Registered
Holder of the Warrant Stock which the Registered Holder anticipated receiving upon such exercise (a “Buy In”), then the Company shall (1) pay in cash to the Registered Holder the amount by which (x) the Registered Holder’s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the amount of Warrant Stock that the Company was required to deliver to the Registered Holder in
connection with the exercise at issue by (B) the closing bid price of the Common Stock at the time of the obligation giving rise to such purchase obligation and (2) at the option of the Registered Holder, either reinstate the portion of the Warrant
and equivalent amount of Warrant Stock for which such exercise was not honored or deliver to the Registered Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery
obligations hereunder. The Registered Holder shall provide the Company written notice indicating the amounts payable to the Registered Holder in respect of the Buy In. 
  
 (iv) The Company’s obligations to issue and deliver Warrant Stock in accordance with the terms hereof are absolute and
unconditional, irrespective of any action or inaction by the Registered Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any
setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Registered Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Registered Holder or any
other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Registered Holder in connection with the issuance of Warrant Stock. Nothing herein shall limit a Registered Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates
representing Warrant Stock upon exercise of the Warrant as required pursuant to the terms hereof. 
  
 2. Warrant Repurchase. If at any time following the Date of Issuance, (i) the closing bid price of the Common Stock for each of the 15 consecutive
trading days immediately prior to delivery 

  

 -3- 

 
of a Call Notice is greater than the Call Price (as defined below), (ii) the average daily trading volume of the Common Stock during the entire 15 trading
day period referenced in clause (i) above through the expiration of the Call Date (as defined below) as set forth in the Company’s notice pursuant to this Section (the “Call Condition Period”) shall be at least 50,000 shares
(subject to equitable adjustment as a result of intervening stock splits and reverse stock splits), (iii) the Warrant Stock is either registered for resale pursuant to an effective registration statement naming the Registered Holder as a selling
stockholder thereunder (and the prospectus thereunder is available for use by the Registered Holder as to all Warrant Stock) or freely transferable without volume restrictions pursuant to Rule 144(k) promulgated under the Act, as determined by
counsel to the Company pursuant to a written opinion letter addressed and in form and substance reasonably acceptable to the Registered Holder and the transfer agent for the Common Stock, during the entire Call Condition Period, (iv) the Company
shall have complied in all material respects with its obligations under this Warrant and the Purchase Agreement and the Common Stock shall at all times be listed or quoted on a trading market during the entire Call Condition Period, and (v) the
Board of Directors of the Company determines that it has sufficient financial resources to effectuate the purchase of this Warrant, then the Company may, in its sole discretion, purchase all (but not less than all) of the then unexercised portion of
this Warrant for an amount equal to the product of the Call Price multiplied by the number of shares of Common Stock for which this Warrant may still be exercised, on the date that is the thirtieth (30th) day after written notice thereof (a “Call Notice”) is received by the Registered Holder (the “Call Date”) at the address
last shown on the records of the Company for the Registered Holder or given by the Registered Holder to the Company for the purpose of notice; provided, that the conditions to giving such notice must be in effect at all times during the Call
Condition Period and the Company shall deliver any payment hereunder to the Holder in immediately available funds within one trading day of the Call Date, or any such Call Notice shall be null and void. The Company and the Registered Holder agree
that, if and to the extent Section 1(b) of this Warrant would restrict the ability of the Registered Holder to exercise this Warrant in the event of a delivery of a Call Notice, then notwithstanding anything to the contrary set forth in the Call
Notice, the Call Notice shall be deemed automatically amended to apply only to such portion of this Warrant as may be exercised by the Registered Holder by the Call Date in accordance with such Sections as are then in effect. The Registered Holder
will promptly (and, in any event, prior to the Call Date) notify the Company in writing following receipt of a Call Notice if Section 1(b) would restrict its exercise of the Warrant, specifying therein the number of Warrant Shares so restricted. The
Company covenants and agrees that it will honor all Exercise Notices tendered through 6:30 p.m. (New York City time) on the Call Date. The “Call Price” shall be $3.50 (subject to equitable adjustment as a result of the events set
forth in Section 3). 
  
 3. Adjustment Of Call Price, Exercise
Price And Number Of Shares. The number of shares of Warrant Stock issuable upon exercise of this Warrant (or any shares of stock or other securities or property receivable or issuable upon exercise of this Warrant), the Exercise Price, and the
Call Price are subject to adjustment upon occurrence of the following events: 
  
 (a) Adjustment for Stock Splits, Dividends, Distributions of Stock, Stock Subdivisions or Combinations of Shares. The Exercise Price and the Call Price of this Warrant shall be proportionally decreased to
reflect any stock split, stock dividend, distribution of stock or subdivision of the Company’s Common Stock. The Exercise Price and the Call Price of this Warrant shall be proportionally increased to reflect any combination of the
Company’s Common 

  

 -4- 

 
Stock. In each case, the Exercise Price and/or the Call Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. 
  
 (b) Fundamental Transactions. If, at any time while this Warrant is outstanding there is a Fundamental Transaction,
then the Registered Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental
Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the amount of Warrant Stock then issuable upon exercise in full of this Warrant (the “Alternate Consideration”). For purposes of any such
exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Registered Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. If any Fundamental Transaction is consummated prior to the second anniversary of the date hereof, at the Registered Holder’s option and request, any successor to the Company or surviving entity in such Fundamental
Transaction shall issue to the Registered Holder a new warrant substantially in the form of this Warrant and consistent with the foregoing provisions and evidencing the Registered Holder’s right to purchase the Alternate Consideration for the
aggregate Exercise Price upon exercise thereof. If any Fundamental Transaction is consummated after the second anniversary of the date hereof, to the extent the consideration in such Fundamental Transaction consists solely of cash, and the cash
consideration to be received by the Registered Holder from the Fundamental Transaction (if the Registered Holder had exercised the Warrant in accordance with the terms hereof) is not greater than or equal to 30% over the Exercise Price, then at the
request of the Registered Holder delivered before the 30th day after such Fundamental Transaction, the Company (or
any such successor or surviving entity) will purchase the Warrant from the Registered Holder for a purchase price, payable in cash within five trading days after such request (or, if later, on the effective date of the Fundamental Transaction),
equal to the Black Scholes value (assuming 100% volatility for the purpose of such calculation) of the remaining unexercised portion of this Warrant on the date of such request. If the consideration to be received by the Registered Holder from the
Fundamental Transaction (if the Registered Holder had exercised the Warrant in accordance with the terms hereof) is greater than or equal to 30% over the Exercise Price, at the Registered Holder’s option and request, any successor to the
Company or surviving entity in such Fundamental Transaction shall issue to the Registered Holder a new warrant substantially in the form of this Warrant and consistent with the foregoing provisions and evidencing the Registered Holder’s right
to purchase the Alternate Consideration for the aggregate Exercise Price upon exercise thereof. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity
to comply with the provisions of this paragraph and insuring that the Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. A “Fundamental Transaction”
means any of the following: (1) the Company effects any merger or consolidation of the Company 

  

 -5- 

 
with or into another person, (2) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (3) any
tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (4) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property. 
  
 (c) Subsequent Issuances. While this Warrant is outstanding, if the Company or any subsidiary thereof, as applicable,
shall at any time issue shares of Common Stock or Common Stock equivalents entitling any person to acquire shares of Common Stock, at a price per share less than the Exercise Price (if the holder of the Common Stock or Common Stock equivalent so
issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights issued in connection with such issuance, be entitled
to receive shares of Common Stock at a price less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price), then, the Exercise Price shall be reduced to equal such lower price; provided, however, that
in no event shall the Exercise Price be reduced to be below the closing price of the Company’s Common Stock on the date of the First Closing. Such adjustment shall be made whenever such Common Stock or Common Stock equivalents are issued. The
Company shall notify the Holder in writing, no later than the trading day following the issuance of any Common Stock or Common Stock equivalent subject to this section, indicating therein the applicable issuance price, or of applicable reset price,
exchange price, conversion price and other pricing terms. Notwithstanding the foregoing, no reduction to the Exercise Price shall occur (A) upon the grant, issuance, exercise or conversion of any options or other securities to employees, officers,
directors or consultants of the Company under stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements approved by the Company’s stockholders or board of directors, (B) pursuant to a bona fide firm
commitment underwritten public offering at a per share offering price equal to at least the market price and in an aggregate offering amount greater than $15,000,000, (C) in connection with a bona fide joint venture or development agreement, merger,
stock acquisition or strategic partnership, the primary purpose of which is not to raise equity capital or (D) in connection with the incurrence of non-convertible debt pursuant to a credit facility entered into with a bank in which a limited number
of warrants are issued as a component of the transaction. 
  
 (d)
Amount of Warrant Stock. Simultaneously with any adjustment to the Exercise Price pursuant to this Section 3, the amount of Warrant Stock that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so
that after such adjustment the aggregate Exercise Price payable hereunder for the adjusted amount of Warrant Stock shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. 
  
 (e) Adjustment Certificate. When any adjustment is required to be made
in the Warrant Stock pursuant to this Section 3, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief statement of the facts requiring such adjustment, (ii) the kind and amount of stock or other securities
or property into which this Warrant shall be exercisable after such adjustment. 
  

 -6- 

 (f) Notice of Corporate Events. If the Company (i) declares a dividend or any other distribution
of cash, securities or other property in respect of its Common Stock, including without limitation any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves,
enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the Company shall deliver to the
Registered Holder a notice describing the material terms and conditions of such transaction (but only to the extent such disclosure would not result in the dissemination of material, non-public information to the Registered Holder) at least 10
calendar days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order
to insure that the Registered Holder is given the practical opportunity to exercise this Warrant prior to such time so as to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. 
  
 4. No Rights as Stockholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or exercise any rights by
virtue hereof as a stockholder of the Company. 
  
 5. No
Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such
fraction multiplied by the closing bid price of Common Stock on the trading date immediately prior to the exercise date, as quoted on the Nasdaq National Market. 
  
 6. Transfers. 
  
 (a) Unregistered Security. Each holder of this Warrant acknowledges that this Warrant, the Warrant Stock and the Common Stock of the Company have
not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and agrees not to sell, pledge, distribute, offer for sale, transfer or otherwise dispose of this Warrant, any Warrant Stock issued upon its exercise
or any Common Stock issued upon conversion of the Warrant Stock in the absence of (i) an effective registration statement under the Act as to this Warrant, such Warrant Stock or such Common Stock and registration or qualification of this Warrant,
such Warrant Stock or such Common Stock under any applicable U.S. federal or state securities law then in effect or (ii) an opinion of counsel, satisfactory to the Company, that such registration and qualification are not required. Each certificate
or other instrument for Warrant Stock issued upon the exercise of this Warrant shall bear a legend substantially to the foregoing effect. The Company shall cause all Warrant Stock registered pursuant hereunder to be listed, prior to the date of the
first sale of such Warrant Stock pursuant to such registration, on each securities exchange on which similar securities issued by the Company are then listed. 
  

(b) Transferability. Subject to the provisions of Section 6(a) hereof, this Warrant and all rights hereunder are transferable, in whole or in
part, upon surrender of the Warrant with a properly executed assignment (in the form of Exhibit B hereto) at the principal office of the 

  

 -7- 

 
Company. This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the
preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Registered Holder any legal or equitable right, remedy or cause of action under this Warrant. 
  
 (c) Warrant Register. The Company will maintain a register containing
the names and addresses of the Registered Holders of this Warrant. Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant as the absolute owner hereof for all purposes;
provided, however, that if this Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary.
Any Registered Holder may change such Registered Holder’s address as shown on the warrant register by written notice to the Company requesting such change. Upon any transfer or assignment, the Company shall register the transfer of any portion
of this Warrant into records maintained by the Company for such purpose, upon surrender of this Warrant, with the Form of Assignment attached hereto duly completed and signed, to the Company at its address specified herein. Upon any such
registration or transfer, a new Warrant to purchase Common Stock, in substantially the form of this Warrant (any such new Warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee
and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Registered Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations of a holder of a Warrant. 
  
 7. Termination. This Warrant (and the right to purchase securities upon exercise hereof) shall terminate automatically on the date which is five years after the date of issuance of this Warrant. 
  
 8. Reservation of Stock. The Company will at all times reserve and
keep available, solely for the issuance and delivery upon the exercise of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. 
  
 9. Exchange of Warrants. Upon the surrender by the Registered Holder
of any Warrant or Warrants, properly endorsed, to the Company at the principal office of the Company, the Company will issue and deliver to or upon the order of such Registered Holder, at the Company’s expense, a new Warrant or Warrants of like
tenor, in the name of such Registered Holder or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face or faces thereof for the number of shares of Warrant
Stock called for on the face or faces of the Warrant or Warrants so surrendered. 
  
 10. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon
delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a
new Warrant of like tenor. 
  

 -8- 

 11. Mailing of Notices. All notices and other communications required or permitted hereunder shall
be in writing and shall be sent by personal delivery, facsimile, overnight courier or mailed by certified or registered mail, postage prepaid, return receipt requested, (a) if to the Registered Holder, to the address or facsimile number of the
Registered Holder most recently furnished in writing to the Company and (b) if to the Company, to the following address or facsimile number: 
  
 Curon Medical, Inc. 
 46117 Landing Parkway

 Fremont, CA 94538 
 Facsimile:
(510) 661-1899 
 Attention: President 
  
 with a copy to: 
  
 Wilson Sonsini Goodrich & Rosati, P.C. 
 650 Page Mill Road 
 Palo Alto, CA 94304 
 Facsimile: (650) 493-6811 
 Attention: David J. Saul 
  
 or to such other facsimile number or address provided to the parties hereunder. Such notices
or other communications shall be deemed delivered upon receipt, in the case of overnight delivery, personal delivery or facsimile transmission (as evidenced by the confirmation thereof), or 3 days after deposit in the mails (as determined by
reference to the postmark). 
  
 12. Amendment or Waiver.
Any term of this Warrant may be amended or waived as set forth in the Purchase Agreement, or upon written consent of the Company and the Registered Holder. Any amendment or waiver effected in accordance with this section shall be binding upon the
Company, the Registered Holder and each transferee of this Warrant. 
  
 13. Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision shall be excluded from this Warrant and the balance of the Warrant shall be interpreted as if such
provision were so excluded and shall be enforceable in accordance with its terms. 
  
 14. Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
  
 15. Governing Law. This Warrant shall be governed, construed and
interpreted in accordance with the laws of the State of California. 
  
 [Signature Page Follows] 
  

 -9- 

 The Company has executed this Warrant as of the date first written above. 
  

			
	 CURON MEDICAL, INC.

		
	 By:
	 	  

	 	 	 Larry Heaton

	 	 	 President and Chief Executive Officer

  

 [Signature Page to Curon Medical, Inc. Warrant] 

 EXHIBIT A 
 EXERCISE NOTICE 
 CURON MEDICAL, INC. 
 WARRANT DATED [    ], 2005 
  
 The undersigned Registered Holder hereby irrevocably elects to purchase
                 shares of Common Stock pursuant to the above referenced Warrant. Capitalized terms used herein and not otherwise defined have the respective
meanings set forth in the Warrant. 
  
 The undersigned Registered Holder hereby
exercises its right to purchase an amount of Warrant Stock equal to                      pursuant to the Warrant. 
  
 The Registered Holder intends that payment of the Exercise Price shall be made as (check
one): 
  
                       “Cash Exercise” under Section [    ] 
  
                       “Cashless Exercise” under Section [    ] 
  
 If the holder has elected a Cash Exercise, the holder shall pay the sum of $
                 to the Company in accordance with the terms of the Warrant. 
  
 Pursuant to this Exercise Notice, the Company shall deliver to the holder an amount of Warrant Stock equal to
                     in accordance with the terms of the Warrant. 
  
 By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby the Registered Holder will not beneficially own in excess of the number of shares of Common Stock (determined in accordance with Section 13(d) of the 1934 Act) permitted to be owned under Section 1(b) of this Warrant to which this
notice relates. 
  

					
	 Dated:                 ,
        
	  	 Name of Registered Holder:

		
	 	  	 (Print)
                                        
                                        
            

			
	 	  	 By:
	 	  

	 	  	 Name:
	 	  

	 	  	 Title:
	 	  

		
	 	  	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)

  
  

 Warrant Stock Exercise Log 
  

							
	 Date

	 	 Amount of
 Warrant Stock
 Available to be
 Exercised

	 	 Amount of Warrant
 Stock Exercised

	  	 Amount of
 Warrant Stock
 Remaining to be
 Exercised

  
  

 EXHIBIT B 
  
 ASSIGNMENT FORM 
  
 FOR VALUE RECEIVED,
                                        
                                        
                 hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant with respect to the number of shares of Common
Stock covered thereby set forth below, unto: 
  

					
	 Name of Assignee

	 	 Address/Facsimile Number

	 	 No. of Shares

  

					
	 Dated:                 
	  	Signature:	 	  

	 	  	 	 	  

	 	  	Witness:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]